Evaluation of performance measures in predictive artificial intelligence models to support medical decisions: overview and guidance
Open accessAbstract
Numerous measures have been proposed to illustrate the performance of predictive artificial intelligence (AI) models. Selecting appropriate performance measures is essential for predictive AI models intended for use in medical practice. Poorly performing models are misleading and may lead to wrong clinical decisions that can be detrimental to patients and increase financial costs. In this Viewpoint, we assess the merits of classic and contemporary performance measures when validating predictive AI models for medical practice, focusing on models that estimate probabilities for a binary outcome. We discuss 32 performance measures covering five performance domains (discrimination, calibration, overall performance, classification, and clinical utility) along with corresponding graphical assessments. The first four domains address statistical performance, whereas the fifth domain covers decision-analytical performance. We discuss two key characteristics when selecting a performance measure and explain why these characteristics are important: (1) whether the measure's expected value is optimised when calculated using the correct probabilities (ie, whether it is a proper measure) and (2) whether the measure solely reflects statistical performance or decision-analytical performance by properly accounting for misclassification costs. 17 measures showed both characteristics, 14 showed one, and one (F1 score) showed neither. All classification measures were improper for clinically relevant decision thresholds other than when the threshold was 0·5 or equal to the true prevalence. We illustrate these measures and characteristics using the ADNEX model which predicts the probability of malignancy in women with an ovarian tumour. We recommend the following measures and plots as essential to report: area under the receiver operating characteristic curve, calibration plot, a clinical utility measure such as net benefit with decision curve analysis, and a plot showing probability distributions by outcome category.
AI snapshot
Written from the paper’s full text.
TL;DR
This Viewpoint evaluates 32 performance measures for predictive AI models with binary outcomes across five domains and argues that measures should be proper and clearly focused on either statistical or decision-analytical performance. It recommends reporting AUROC, a calibration plot, a clinical utility measure such as net benefit with decision curve analysis, and a plot of probability distributions by outcome category.
Key findings
- Of 32 measures, 17 showed both key characteristics (properness and clear statistical or decision-analytical focus), 14 showed one, and F1 showed neither; all classification measures were improper at clinically relevant decision thresholds other than when the threshold was 0·5 or equal to the true prevalence.
- In the ADNEX external validation case study (n=894; 434 malignant; prevalence 49%), AUROC was 0·911 (95% CI 0·894–0·927); the O:E ratio was 1·228 (1·171–1·288) before recalibration and 1·000 (0·955–1·046) after; net benefit at t=0·1 was 0·443 (0·411–0·475) before and 0·444 (0·411–0·478) after recalibration.
- Recalibration improved all strictly proper measures and left semi-proper measures improved or unchanged, while most improper classification summary measures worsened (e.g., classification accuracy 0·794 to 0·691; F1 0·818 to 0·756; MCC 0·625 to 0·480).
- The recommended core set is AUROC, a smoothed calibration plot, a clinical utility measure such as net benefit with decision curve analysis, and a figure showing probability distributions for each outcome category.
Methods
- Viewpoint assessing classic and contemporary performance measures for predictive AI models that estimate probabilities for a binary outcome; 32 measures were classified into five domains: discrimination, calibration, overall performance, classification, and clinical utility.
- Illustrative case study: external validation of the ADNEX model for predicting malignancy in women with an ovarian tumour, using TransIOTA data from 894 women (434 malignant, prevalence 49%) recruited between 2015 and 2019 in one secondary and five tertiary care centres in four countries.
- All discussed measures were calculated with 95% CIs using the percentile bootstrap method on 1000 bootstrap samples, before and after logistic recalibration; code and risk estimates/outcomes are available in a GitHub repository, while the complete dataset cannot be publicly shared owing to privacy considerations.
Limitations
- Stated: the Viewpoint focused only on performance measures for binary outcomes, did not address counterfactual prediction, could not discuss all measures, and did not directly discuss model comparisons in depth.
- Stated: calibration and performance-measure research is ongoing, including work on strong calibration, quantifying miscalibration, and uncertainty.
- Evident: as a Viewpoint rather than a systematic review, the recommendations are based on selected measures and a single case study (ADNEX external validation), so generalizability to other outcomes and settings is not empirically tested here.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
0 of 91 cited sources checked · 0 supported · 0 flagged
- Findingnone given§ Evaluation of performance measures in predictive artificial intelligence models to support medical decisions: overview and guidance · p. 1
All classification measures were improper for clinically relevant decision thresholds other than when the threshold was 0.5 or equal to the true prevalence.
“All classification measures were improper for clinically relevant decision thresholds other than when the threshold was 0 ⋅ 5 or equal to the true prevalence.”
Quote in the paperSubstantial claim - Findingown data§ Calibration · p. 6
The ADNEX calibration plots lie mostly above the diagonal.
“The plots lie mostly above the diagonal”
Quote in the paperNot a substantial claim - Findingown data§ Calibration · p. 5
ADNEX had an O:E ratio of 1.23 (95% CI 1.17-1.29), indicating that 23% more events were observed than expected based on the model.
“ADNEX had an O:E ratio of 1 ⋅ 23 (95% CI 1 ⋅ 17-1 ⋅ 29), indicating that 23% more events were observed than expected based on the model (table 1).”
Quote in the paperNot a substantial claim - Findingown data§ Calibration · p. 6
In the ADNEX case study, the model had a calibration slope of 0.93 (95% CI 0.83-1.05).
“In our case study, the ADNEX model had a calibration slope of 0 ⋅ 93 (95% CI 0 ⋅ 83-1 ⋅ 05)”
Quote in the paperNot a substantial claim - Findingown data§ Results after recalibration · p. 8
The improper summary measures for classification (except diagnostic odds ratio) worsened remarkably after recalibration.
“The improper summary measures for classification (except diagnostic odds ratio) worsened remarkably.”
Quote in the paperSubstantial claim
- Findingown data§ Overall performance · p. 6
In the ADNEX model, patients with benign tumour mostly had very low estimated probabilities of malignancy.
“Figure 3 shows violin plots for the ADNEX model, indicating that patients with benign tumour mostly had very low estimated probabilities of malignancy.”
Quote in the paperNot a substantial claim - Findingnone given§ Results after recalibration · p. 8
The improper measures for overall performance improved after recalibration.
“The improper measures for overall performance improved.”
Quote in the paperSubstantial claim - Findingown data§ Clinical utility · p. 7
The (standardised) net benefit was better for ADNEX than for the reference strategies across all reasonable decision thresholds.
“The (standardised) net benefit was better for ADNEX than for the reference strategies across all reasonable decision thresholds (figure 4A-B).”
Quote in the paperSubstantial claim- The authors state this as an assumption: The range of reasonable decision thresholds is 0.05 to 0.40 (normalised cost of false negatives between 0.60 and 0.95).
- Findingnone given§ Clinical utility · p. 7
For a normalised cost of a false negative of 0.9, expected cost was minimised to 0.35 at t=0.06.
“For a normalised cost of a false negative of 0 ⋅ 9, expected cost was minimised to 0 ⋅ 35 at t =0 ⋅ 06.”
Quote in the paperNot a substantial claim - Findingown data§ Overall performance · p. 6
In the ADNEX model, patients with malignancy mostly had moderate-to-high estimated probabilities, with less peaked distribution.
“Patients with malignancy mostly had moderate-to-high estimated probabilities, with less peaked distribution.”
Quote in the paperNot a substantial claim - Findingown data§ Results after recalibration · p. 8
All strictly proper measures improved after recalibration.
“All strictly proper measures improved after recalibration.”
Quote in the paperSubstantial claim - Findingown data§ Clinical utility · p. 7
The net benefit of the ADNEX model at t=0.1 was 0.44.
“The net benefit of the model at t =0 ⋅ 1 was 0 ⋅ 44.”
Quote in the paperNot a substantial claim - Findingown data§ Results after recalibration · p. 8
Semi-proper measures either improved or remained unchanged after recalibration.
“Semi-proper measures either improved or remained unchanged.”
Quote in the paperSubstantial claim - Findingnone given§ Results after recalibration · p. 8
The calibration plot is closer to the diagonal after recalibration in the validation dataset.
“The calibration plot is closer to the diagonal after recalibration in the validation dataset.”
Quote in the paperNot a substantial claim - Findingown data§ Clinical utility · p. 7
The expected cost curve gives the same impression as net benefit for ADNEX.
“The expected cost curve gives the same impression (figure 4C).”
Quote in the paperNot a substantial claim- The authors state this as an assumption: The range of reasonable decision thresholds is 0.05 to 0.40 (normalised cost of false negatives between 0.60 and 0.95).
- Findingcitation§ Discussion · p. 9
Calibration measures are still under-reported.
“Unfortunately, calibration measures are still under-reported.”
Quote in the paperNot a substantial claim0 of 3 sources checked- cites [92] Wynants, 2020, Prediction models for diagnosis and prognosis of COVID-19: systematic review and critical appraisal, BMJ
Not checked in the free run.
- cites [93] Andaur Navarro, 2021, Risk of bias in studies on prediction models developed using supervised machine learning techniques: systematic review, BMJ
Not checked in the free run.
- cites [94] Dhiman, 2022, Methodological conduct of prognostic prediction models developed using machine learning in oncology: a systematic review, BMC Med Res Methodol source
Not checked in the free run.
- Premisecitation§ Case study: external validation of a diagnostic model for ovarian cancer · p. 3
The ADNEX model preoperatively estimates the probability of malignancy in women with an ovarian tumour who are scheduled for surgery.
“The ADNEX model, developed by the International Ovarian Tumor Analysis (IOTA) consortium (authors BVC and DT are part of this consortium), preoperatively estimates the probability of malignancy in women with an ovarian tumour who are scheduled for surgery. 31”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [31] Van Calster, 2014, Evaluating the risk of ovarian cancer before surgery using the ADNEX model to differentiate between benign, borderline, early and advanced stage invasive, and secondary metastatic tumours: prospective multicentre diagnostic study, BMJ source
Not checked in the free run.
- Premisereasoning§ Case study: external validation of a diagnostic model for ovarian cancer · p. 3
Logistic recalibration essentially applies a linear transformation to the linear predictor.
“Logistic recalibration essentially applies a linear transformation to the linear predictor.”
Quote in the paperNot a substantial claim - Premisecitation§ Overall performance · p. 6
Scaled Brier and R-squared measures are asymptotically strictly proper (strictly proper when sample size is high, for instance, above 100).
“scaled Brier and R-squared measures are asymptotically strictly proper (ie, strictly proper when sample size is high, for instance, above 100)”
Quote in the paperNot a substantial claim0 of 3 sources checked- cites [26] Buja
Not checked in the free run.
- cites [27] Gneiting, 2007, Strictly proper scoring rules, prediction, and estimation, J Am Stat Assoc source
Not checked in the free run.
- cites [71] Van Houwelingen, 2012
Not checked in the free run.
- Interpretationown data§ Calibration · p. 6
The spread of the ADNEX model's estimated probabilities was adequate.
“suggesting that the spread of the probabilities was adequate.”
Quote in the paperNot a substantial claim - Interpretationreasoning§ Panel: Defining a decision threshold · p. 3
Using the 0.1 decision threshold accepts up to nine false positives per true positive.
“In other words, we accept up to nine false positives (ie, performing advanced surgery in up to nine patients with benign tumour) per true positive.”
Quote in the paperNot a substantial claim- The authors state this as an assumption: Using a decision threshold of 0.1 for probability of malignancy assumes that the medical benefit of advanced surgery on a malignant tumour is nine times greater than the harm of unnecessary advanced surgery in individuals with a benign tumour.
- Interpretationreasoning§ Calibration · p. 6
Grouped calibration plots cannot comprehensively address moderate calibration because individuals with very different estimated probabilities might still end up in the same group.
“Grouped plots cannot be used to comprehensively address moderate calibration because individuals with very different estimated probabilities might still end up in the same group.”
Quote in the paperSubstantial claim - Premisereasoning§ Calibration · p. 6
All discussed calibration measures have a focus on statistical performance.
“with a focus on statistical performance (second key characteristic).”
Quote in the paperNot a substantial claim - Premisecitation§ Calibration · p. 6
During internal validation, a calibration slope less than 1 can indicate potential overfitting.
“During internal validation, a calibration slope less than 1 can indicate potential overfitting.”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [54] Van Calster, 2019, Calibration: the Achilles heel of predictive analytics, BMC Med source
Not checked in the free run.
- Premisenone given§ Discrimination · p. 5
For AUPRC, the PR curve does not directly consider true negatives.
“For AUPRC, the PR curve does not directly consider true negatives.”
Quote in the paperSubstantial claim - Interpretationreasoning§ Calibration · p. 6
A probable reason for the underestimation is that five of six participating centres were tertiary care centres, resulting in a high prevalence of malignancy (49%).
“A probable reason is that fi ve of six participating centres in the validation study were tertiary care centres, resulting in a high prevalence of malignancy (49%).”
Quote in the paperNot a substantial claim - Interpretationcitation§ Panel: Defining a decision threshold · p. 3
Suggesting advanced surgery to patients who actually have a 10% risk of malignancy based on the ADNEX predictors implies performing advanced surgery in ten individuals per true positive.
“Suggesting advanced surgery to patients who actually have a 10% risk of malignancy based on the ADNEX predictors implies performing advanced surgery in ten individuals per true positive (ie, performing advanced surgery in a patient with a malignant tumour). 18”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [18] Pauker, 1975, Therapeutic decision making: a cost-benefit analysis, N Engl J Med source
Not checked in the free run.
- The authors state this as an assumption: Using a decision threshold of 0.1 for probability of malignancy assumes that the medical benefit of advanced surgery on a malignant tumour is nine times greater than the harm of unnecessary advanced surgery in individuals with a benign tumour.
- Interpretationreasoning§ Discrimination · p. 5
For pAUROC, there is no decision-analytical basis for this approach.
“Consequently, there is no decision-analytical basis for this approach.”
Quote in the paperSubstantial claim - Interpretationown data§ Calibration · p. 6
The ADNEX model's estimated probabilities were underestimations across the whole range.
“suggesting that the probabilities were underestimations across the whole range.”
Quote in the paperNot a substantial claim - Premisecitation§ Calibration · p. 6
All discussed calibration measures are semi-proper.
“All discussed calibration measures are semi-proper, 52”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [52] Van Calster, 2016, A calibration hierarchy for risk models was defined: from utopia to empirical data, J Clin Epidemiol source
Not checked in the free run.
- Premisenone given§ Properness · p. 2
In any given dataset, particularly when sample size is low, the correct model can be outperformed by an incorrect model due to random variation.
“In any given dataset, particularly when sample size is low, the correct model can be outperformed by an incorrect model due to random variation.”
Quote in the paperSubstantial claim - Premisecitation§ Calibration · p. 6
The proposed summary measures for calibration plots (ECE, ECI, ICI) cannot inform on the direction of miscalibration.
“Similar to statistical tests such as the Hosmer-Lemeshow test, the proposed summary measures cannot inform on the direction of miscalibration.”
Quote in the paperSubstantial claim0 of 2 sources checked- cites [54] Van Calster, 2019, Calibration: the Achilles heel of predictive analytics, BMC Med source
Not checked in the free run.
- cites [61] Nattino, 2020, Assessing the goodness of fit of logistic regression models in large samples: a modification of the Hosmer-Lemeshow test, Biometrics source
Not checked in the free run.
- Interpretationcitation§ Discrimination · p. 5
There are no grounds to label AUROC as misleading or overoptimistic.
“There are no grounds to label AUROC as misleading or overoptimistic. 36,49”
Quote in the paperNot a substantial claim0 of 2 sources checked- cites [36] Berrar, 2012, Caveats and pitfalls of ROC analysis in clinical microarray research (and how to avoid them), Brief Bioinform source
Not checked in the free run.
- cites [49] McDermott, 2024, A closer look at AUROC and AUPRC under class imbalance, Adv Neural Inf Process Syst
Not checked in the free run.
- Interpretationreasoning§ Discrimination · p. 5
Unlike AUROC, AUPRC and pAUROC do not have a clear focus.
“Unlike AUROC, AUPRC and pAUROC do not have a clear focus (second key characteristic).”
Quote in the paperSubstantial claim - Interpretationreasoning§ Results after recalibration · p. 8
The worsening of most improper performance measures after recalibration illustrates the importance of the properness concept.
“The worsening of most improper performance measures after recalibration illustrates the importance of the properness concept.”
Quote in the paperSubstantial claim - Premisecitation§ Classification measures · p. 6
The absolute value of F1 changes by simply switching the outcome labels (when 1 becomes 0 and 0 becomes 1).
“(3) the absolute value of F1 changes by simply switching the outcome labels (ie, when 1 becomes 0 and 0 becomes 1).”
Quote in the paperNot a substantial claim0 of 2 sources checked- cites [77] Chicco, 2020, The advantages of the Matthews correlation coefficient (MCC) over F1 score and accuracy in binary classification evaluation, BMC Genomics source
Not checked in the free run.
- cites [78] Christen, 2024, A review of the F-measure: its history, properties, criticism, and alternatives, ACM Comput Surv source
Not checked in the free run.
- Interpretationreasoning§ Results after recalibration · p. 8
Recalibration cannot improve discrimination measures such as AUROC because they are based on ranks.
“For example, owing to the rankpreserving updating method, recalibration cannot improve discrimination measures such as AUROC as they are based on ranks.”
Quote in the paperNot a substantial claim - Premisecitation§ Classification measures · p. 6
These issues hold for the more general F beta class of measures, of which F1 is a special case.
“These issues hold for the more general F beta class of measures, of which F1 is a special case.”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [78] Christen, 2024, A review of the F-measure: its history, properties, criticism, and alternatives, ACM Comput Surv source
Not checked in the free run.
- Premisecitation§ Clinical utility · p. 7
The most used measure for clinical utility in prediction studies in health care is net benefit.
“The most used measure for clinical utility in prediction studies in health care is net benefit.”
Quote in the paperNot a substantial claim0 of 3 sources checked- cites [21] Vickers, 2006, Decision curve analysis: a novel method for evaluating prediction models, Med Decis Making source
Not checked in the free run.
- cites [82] Vickers, 2016, Net benefit approaches to the evaluation of prediction models, molecular markers, and diagnostic tests, BMJ
Not checked in the free run.
- cites [83] Kerr, 2019, Assessing the clinical impact of risk models for opting out of treatment, Med Decis Making source
Not checked in the free run.
- Premisecitation§ Classification measures · p. 6
Some classification measures (balanced accuracy, Youden, and F1) are semi-proper when t=0.5 (classification accuracy) or when t equals the true prevalence.
“Some classification measures (balanced accuracy, Youden, and F1) are semi-proper when t =0 ⋅ 5 (classification accuracy) or when t equals the true prevalence”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [26] Buja
Not checked in the free run.
- Premisecitation§ Classification measures · p. 6
F1 ignores true negatives.
“(1) F1 ignores true negatives”
Quote in the paperSubstantial claim0 of 2 sources checked- cites [77] Chicco, 2020, The advantages of the Matthews correlation coefficient (MCC) over F1 score and accuracy in binary classification evaluation, BMC Genomics source
Not checked in the free run.
- cites [78] Christen, 2024, A review of the F-measure: its history, properties, criticism, and alternatives, ACM Comput Surv source
Not checked in the free run.
- Interpretationnone given§ Classification measures · p. 6
F1 is the only summary measure without a clear focus on statistical performance, as it conflates classification with clinical utility.
“F1 is the only summary measure without a clear focus on statistical performance, as it conflates classification with clinical utility.”
Quote in the paperNot a substantial claim - Premisecitation§ Classification measures · p. 6
At a given relevant decision threshold t, all classification measures are improper.
“At a given relevant decision threshold t , all classification measures are improper (Appendix pp 3-6).”
Quote in the paperSubstantial claim - Premisecitation§ Clinical utility · p. 7
The maximum value of net benefit equals the prevalence.
“The maximum value of net benefit equals the prevalence.”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [84] Kerr, 2016, Assessing the clinical impact of risk prediction models with decision curves: guidance for correct interpretation and appropriate use, J Clin Oncol source
Not checked in the free run.
- Premisecitation§ Classification measures · p. 6
F1 and MCC were introduced to address the challenges caused by class imbalance, where classification accuracy can be inflated by classifying all patients as low risk when the event is rare.
“F1 and MCC were introduced to address the challenges caused by class imbalance, where classification accuracy can be inflated by classifying all patients as low risk when the event is rare.”
Quote in the paperNot a substantial claim0 of 5 sources checked- cites [76] Van Rijsbergen, 1979
Not checked in the free run.
- cites [77] Chicco, 2020, The advantages of the Matthews correlation coefficient (MCC) over F1 score and accuracy in binary classification evaluation, BMC Genomics source
Not checked in the free run.
- cites [78] Christen, 2024, A review of the F-measure: its history, properties, criticism, and alternatives, ACM Comput Surv source
Not checked in the free run.
- cites [79] Baldi, 2000, Assessing the accuracy of prediction algorithms for classification: an overview, Bioinformatics source
Not checked in the free run.
- cites [80] Chicco, 2021, The Matthews correlation coefficient (MCC) is more reliable than balanced accuracy, bookmaker informedness, and markedness in two-class confusion matrix evaluation, BioData Min source
Not checked in the free run.
- Premisecitation§ Classification measures · p. 6
F1 has no intuitive interpretation.
“(2) F1 has no intuitive interpretation”
Quote in the paperNot a substantial claim0 of 2 sources checked- cites [77] Chicco, 2020, The advantages of the Matthews correlation coefficient (MCC) over F1 score and accuracy in binary classification evaluation, BMC Genomics source
Not checked in the free run.
- cites [78] Christen, 2024, A review of the F-measure: its history, properties, criticism, and alternatives, ACM Comput Surv source
Not checked in the free run.
- Premisecitation§ Discussion · p. 10
Meta-analysis and meta-regression methods can be used to quantify and understand heterogeneity in performance across external validation studies.
“Meta-analysis and meta-regression methods can be used to quantify and understand heterogeneity in performance across external validation studies.”
Quote in the paperNot a substantial claim0 of 3 sources checked- cites [102] van Leeuwen, 2025, Instability of the AUROC of clinical prediction models, Stat Med source
Not checked in the free run.
- cites [105] Debray, 2019, A framework for meta-analysis of prediction model studies with binary and time-to-event outcomes, Stat Methods Med Res source
Not checked in the free run.
- cites [106] Barreñada, 2024, ADNEX risk prediction model for diagnosis of ovarian cancer: systematic review and meta-analysis of external validation studies, BMJ Med source
Not checked in the free run.
- Premisecitation§ Discussion · p. 10
More specific sample size calculations are now available for regression-based models.
“More specific sample size calculations are now available for regression-based models.”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [100] Riley, 2021, Minimum sample size for external validation of a clinical prediction model with a binary outcome, Stat Med source
Not checked in the free run.
- Interpretationcitation§ Discussion · p. 10
Naive comparison of models validated using different external datasets, reflecting different populations from different settings, can lead to wrong conclusions.
“Naive comparison of models validated using different external datasets, reflecting different populations from different settings, can lead to wrong conclusions.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [36] Berrar, 2012, Caveats and pitfalls of ROC analysis in clinical microarray research (and how to avoid them), Brief Bioinform source
Not checked in the free run.
- Interpretationreasoning§ Discussion · p. 10
Class imbalance is not as problematic as often claimed.
“We argue that class imbalance is not as problematic as often claimed.”
Quote in the paperNot a substantial claim - Interpretationcitation§ Discussion · p. 9
Miscalibration can compromise predictive AI application by leading to systematic overtreatment or undertreatment.
“Miscalibration can compromise predictive AI application by leading to systematic overtreatment or undertreatment.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [89] Van Calster, 2015, Calibration of risk prediction models: impact on decision-analytic performance, Med Decis Making source
Not checked in the free run.
- Interpretationcitation§ Discussion · p. 10
The net reclassification improvement is improper.
“Dedicated measures, such as the widely used but improper net reclassification improvement, are available for evaluating competing models.”
Quote in the paperNot a substantial claim0 of 3 sources checked- cites [48] Pepe, 2015, The Net Reclassification Index (NRI): a misleading measure of prediction improvement even with independent test data sets, Stat Biosci source
Not checked in the free run.
- cites [118] Pencina, 2008, Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond, Stat Med source
Not checked in the free run.
- cites [119] Leening, 2014, Net reclassification improvement: computation, interpretation, and controversies: a literature review and clinician’s guide, Ann Intern Med source
Not checked in the free run.
- Interpretationcitation§ Discussion · p. 10
Often, more data are needed when comparing calibration between models.
“Often, more data are needed when comparing calibration between models.”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [101] Peek, 2007, External validation of prognostic models for critically ill patients required substantial sample sizes, J Clin Epidemiol source
Not checked in the free run.
- Interpretationreasoning§ Discussion · p. 9
Calibration is more important for external validation, when models are evaluated in different contexts and populations.
“Calibration is more important for external validation, when models are evaluated in different contexts and populations.”
Quote in the paperSubstantial claim - Interpretationcitation§ Discussion · p. 10
Heterogeneity in model performance should be expected based on differences in populations and measurement procedures between locations, settings, or time periods.
“Second, heterogeneity in model performance should be expected based on differences in populations and measurement procedures between locations, settings, or time periods.”
Quote in the paperSubstantial claim0 of 4 sources checked- cites [91] Van Calster, 2023, There is no such thing as a validated prediction model, BMC Med source
Not checked in the free run.
- cites [102] van Leeuwen, 2025, Instability of the AUROC of clinical prediction models, Stat Med source
Not checked in the free run.
- cites [103] Youssef, 2023, External validation of AI models in health should be replaced with recurring local validation, Nat Med source
Not checked in the free run.
- cites [104] Jenkins, 2021, Continual updating and monitoring of clinical prediction models: time for dynamic prediction systems?, Diagn Progn Res source
Not checked in the free run.
- Premisecitation§ Discussion · p. 10
Misclassification costs are informed by the nature and effect of the medical intervention at hand.
“Misclassification costs are informed by the nature and effect of the medical intervention at hand (eg, the decision to perform surgery or not).”
Quote in the paperNot a substantial claim0 of 4 sources checked- cites [21] Vickers, 2006, Decision curve analysis: a novel method for evaluating prediction models, Med Decis Making source
Not checked in the free run.
- cites [82] Vickers, 2016, Net benefit approaches to the evaluation of prediction models, molecular markers, and diagnostic tests, BMJ
Not checked in the free run.
- cites [85] Vickers, 2019, A simple, step-by-step guide to interpreting decision curve analysis, Diagn Progn Res source
Not checked in the free run.
- cites [98] Hand, 2018, A note on using the F-measure for evaluating record linkage algorithms, Stat Comput source
Not checked in the free run.
- Interpretationreasoning§ Discussion · p. 10
The extent of class imbalance is not mathematically proportional to the extent of imbalance in misclassification costs.
“The extent of class imbalance is not mathematically proportional to the extent of imbalance in misclassification costs.”
Quote in the paperSubstantial claim
- Classified as probably not a substantial claim. 62
- May combine two claims. 47
Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
Findingnone given§ Discrimination · p. 5The ADNEX model had an AUROC of 0.91 (95% CI 0.89-0.93) and an AUPRC of 0.89 (95% CI 0.86-0.91).
“The ADNEX model had an AUROC of 0 ⋅ 91 (95% CI 0 ⋅ 89-0 ⋅ 93) and an AUPRC of 0 ⋅ 89 (95% CI 0 ⋅ 86-0 ⋅ 91).”
Quote in the paperNot a substantial claimMay combine two claims.
Findingown data§ Calibration · p. 5The calibration intercept of the ADNEX model was 0.81 (95% CI 0.62-1.01), suggesting underestimation of probabilities on average (intercept > 0).
“The calibration intercept of the ADNEX model was 0 ⋅ 81 (95% CI 0 ⋅ 62-1 ⋅ 01), suggesting underestimation of probabilities on average (intercept > 0).”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Findingnone given§ Discrimination · p. 5Ignoring sensitivity values below 0.8, pAUROC was 0.14 (95% CI 0.13-0.15).
“Ignoring sensitivity values below 0 ⋅ 8, pAUROC was 0 ⋅ 14 (95% CI 0 ⋅ 13-0 ⋅ 15).”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
Findingnone given§ Calibration · p. 6Five of six participating centres in the validation study were tertiary care centres, resulting in a high prevalence of malignancy (49%).
“A probable reason is that fi ve of six participating centres in the validation study were tertiary care centres, resulting in a high prevalence of malignancy (49%).”
Quote in the paperNot a substantial claimMay combine two claims.
Findingnone given§ Evaluation of performance measures in predictive artificial intelligence models to support medical decisions: overview and guidance · p. 117 measures showed both characteristics, 14 showed one, and one (F1 score) showed neither.
“17 measures showed both characteristics, 14 showed one, and one (F1 score) showed neither.”
Quote in the paperSubstantial claimMay combine two claims.
Findingown data§ Results after recalibration · p. 8Some partial classification measures improved (sensitivity and NPV), whereas others worsened (specificity and PPV) after recalibration.
“Some partial classification measures improved (sensitivity and NPV), whereas others worsened (specificity and PPV).”
Quote in the paperSubstantial claimMay combine two claims.
Findingown data§ Classification measures · p. 7At a threshold of 10%, the ADNEX model showed a classification accuracy of 0.79 (95% CI 0.77-0.82), F1 score of 0.82 (0.79-0.84), and MCC of 0.63 (0.58-0.67).
“At a threshold of 10%, the ADNEX model showed a classification accuracy of 0 ⋅ 79 (95% CI 0 ⋅ 77-0 ⋅ 82), F1 score of 0 ⋅ 82 (0 ⋅ 79-0 ⋅ 84), and MCC of 0 ⋅ 63 (0 ⋅ 58-0 ⋅ 67) (table 1).”
Quote in the paperNot a substantial claimMay combine two claims.
Findingcitation§ Classification measures · p. 6At the commonly recommended threshold of 10%, the ADNEX model classified 578 patients as high risk, of whom 414 had a malignant tumour (true positive) and 164 had a benign tumour (false positive); the remaining 316 patients were classified as low risk, of whom 296 had a benign tumour (true negative) and 20 had a malignant tumour (false negative).
“At the commonly recommended threshold of 10% in our case study, 23 ADNEX classified 578 patients as high risk, of whom 414 had a malignant tumour (true positive) and 164 had a benign tumour (false positive). The remaining 316 patients were classified as low risk, of whom 296 had a benign tumour (true negative) and 20 had a malignant tumour (false negative).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [23] Timmerman, 2021, ESGO/ISUOG/IOTA/ESGE consensus statement on preoperative diagnosis of ovarian tumors, Ultrasound Obstet Gynecol source
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing).
Findingcitation§ Discussion · p. 10Calibration is an active area of research focusing on aspects such as strong calibration, quantifying the degree of miscalibration, and uncertainty.
“For example, calibration is an active area of research focusing on aspects such as strong calibration, quantifying the degree of miscalibration, and uncertainty.”
Quote in the paperNot a substantial claim0 of 4 sources checked- cites [62] Arrieta-Ibarra, 2022, Metrics of calibration for probabilistic predictions, J Mach Learn Res
Not checked in the free run.
- cites [113] Perez-Lebel, 2022, Beyond calibration: estimating the grouping loss of modern neural networks, arXiv
Not checked in the free run.
- cites [114] Kompa, 2021, Second opinion needed: communicating uncertainty in medical machine learning, NPJ Digit Med source
Not checked in the free run.
- cites [115] Riley, 2023, Stability of clinical prediction models developed using statistical or machine learning methods, Biom J source
Not checked in the free run.
Probably not a substantial claim: may not pass S2 (checkable), S4 (based). May combine two claims.
Premisenone given§ Panel: Defining a decision threshold · p. 3If misclassification costs influence a performance measure in an implicit or ad hoc way, the measure neither assesses statistical performance nor adequately evaluates the quality of decisions for clinical practice.
“If misclassification costs influence a performance measure in an implicit or ad hoc way, the measure neither assesses statistical performance nor adequately evaluates the quality of decisions for clinical practice.”
Quote in the paperNot a substantial claimClassified as probably not a substantial claim. May combine two claims.
Premisereasoning§ Department of Development · p. 2Discrimination reflects relative performance; it does not matter how high or low the estimated probabilities are, only whether they allow discrimination between individuals with versus without the event.
“Discrimination reflects relative performance; ie, it does not matter how high or low the estimated probabilities are, only whether they allow to discriminate between individuals with versus without the event.”
Quote in the paperSubstantial claimClassified as probably not a substantial claim.
Premisenone given§ Department of Development · p. 2Classification performance is influenced by discrimination and calibration performance.
“Classification performance is influenced by discrimination and calibration performance.”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S2 (checkable). May combine two claims.
Premisereasoning§ Panel: Defining a decision threshold · p. 3Using statistical arguments to set a decision threshold is inconsistent with decision theory and detached from practical use by clinicians.
“Using statistical arguments to set a decision threshold is inconsistent with decision theory and detached from practical use by clinicians.”
Quote in the paperNot a substantial claim- Rests on an assumption: The primary aim of most predictive AI models in medical practice is to support subsequent decision making.
May combine two claims.
Premisereasoning§ Clear focus on statistical or decision-analytical evaluation · p. 2Statistical performance measures are essential for model evaluation but cannot be used to find out whether a model should be used in practice.
“Statistical performance measures are essential for model evaluation but cannot be used to fi nd out whether a model should be used in practice: it is not appropriate to cite, for example, good discrimination and calibration or conclude that a model can be used to aid decisions about ovarian surgery.”
Quote in the paperSubstantial claimClassified as probably not a substantial claim.
Premisereasoning§ Department of Development · p. 2Clinical utility goes one step further by explicitly incorporating misclassification costs when evaluating classifications of individuals into low-risk and high-risk groups.
“The fi fth domain, clinical utility, goes one step further by explicitly incorporating misclassification costs when evaluating classifications of individuals into low-risk and high-risk groups.”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Premisecitation§ Department of Development · p. 1The first three performance domains evaluate performance based on probability estimates.
“Among these domains, the fi rst three evaluate performance based on probability estimates (Appendix p 2).”
Quote in the paperNot a substantial claimClassified as probably not a substantial claim. May combine two claims.
Premisereasoning§ Properness · p. 2When an incorrect model can have a better expected value than the correct model, the measure is termed improper and cannot be trusted.
“When an incorrect model can have a better expected value than the correct model, the measure is termed improper and cannot be trusted.”
Quote in the paperSubstantial claimClassified as probably not a substantial claim. May combine two claims.
Premisereasoning§ Properness · p. 2The importance of properness is that a proper measure cannot be fooled: in expectation, the correct model cannot be outperformed by an incorrect one.
“The importance of properness is that a proper measure cannot be fooled: in expectation, the correct model cannot be outperformed by an incorrect one.”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Premisenone given§ Department of Development · p. 2The fourth and fifth performance domains require a threshold on the estimated risk of the event to classify individuals into two mutually exclusive groups.
“The fourth and fi fth performance domains require a threshold on the estimated risk of the event to classify individuals into two mutually exclusive groups: low-risk (estimated risk below the threshold) and high-risk (estimated risk equal to or above the threshold) groups.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S2 (checkable), S4 (based). May combine two claims.
Premisenone given§ Key characteristics of an informative performance measure · p. 2Measures that do not possess the first characteristic cannot be trusted, whereas measures not possessing the second are equivocal.
“Measures that do not possess the fi rst characteristic cannot be trusted, whereas measures not possessing the second are equivocal.”
Quote in the paperNot a substantial claimMay combine two claims.
Premisecitation§ Introduction · p. 1Poorly performing predictive AI models intended for medical practice are misleading and may lead to wrong clinical decisions that can be detrimental to patients and increase financial costs.
“poorly performing models might lead to wrong clinical decisions that can be detrimental to patients and increase fi nancial costs. 5”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [5] Kamran, 2024, Evaluation of sepsis prediction models before onset of treatment, NEJM AI source
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing).
Premisereasoning§ Department of Development · p. 2Calibration reflects absolute performance by evaluating whether estimates are too high or too low.
“Calibration reflects absolute performance by evaluating whether estimates are too high or too low.”
Quote in the paperNot a substantial claimMay combine two claims.
Premisereasoning§ Department of Development · p. 2Models can have good discrimination but poor calibration, and vice versa.
“Models can therefore have good discrimination but poor calibration, and vice versa.”
Quote in the paperSubstantial claimClassified as probably not a substantial claim.
Premisecitation§ Discrimination · p. 4The definition of discrimination implies that discrimination measures should rely only on the ranks of the estimated probabilities in the dataset.
“The definition of discrimination implies that discrimination measures should rely only on the ranks of the estimated probabilities in the dataset. 36”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [36] Berrar, 2012, Caveats and pitfalls of ROC analysis in clinical microarray research (and how to avoid them), Brief Bioinform source
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing), S4 (based).
Premisenone given§ Calibration · p. 5Research on the quantification of a fourth level, strong calibration, is ongoing.
“Research on the quantification of a fourth level, strong calibration, is ongoing.”
Quote in the paperNot a substantial claimClassified as probably not a substantial claim.
Premisecitation§ Panel: Defining a decision threshold · p. 3A decision threshold of 0.1 (10%) for the probability of malignancy is often recommended.
“A decision threshold of 0 ⋅ 1 (10%) for the probability of malignancy is often recommended. 23”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [23] Timmerman, 2021, ESGO/ISUOG/IOTA/ESGE consensus statement on preoperative diagnosis of ovarian tumors, Ultrasound Obstet Gynecol source
Not checked in the free run.
- Rests on an assumption: The primary aim of most predictive AI models in medical practice is to support subsequent decision making.
Classified as probably not a substantial claim. May combine two claims.
Premisenone given§ Discrimination · p. 5Discrimination measures are not meant to reflect differential misclassification costs, and class imbalance should not be conflated with misclassification costs or medical relevance.
“Discrimination measures are not meant to reflect differential misclassification costs, and class imbalance should not be conflated with misclassification costs or medical relevance.”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Premisecitation§ Case study: external validation of a diagnostic model for ovarian cancer · p. 3ADNEX was developed on data from 5909 individuals recruited between 1999 and 2012 in 24 secondary and tertiary care centres from 10 countries.
“ADNEX was developed on the data from 5909 individuals recruited between 1999 and 2012 in 24 secondary and tertiary care centres from 10 countries (Italy, Belgium, Sweden, Czech Republic, Poland, France, United Kingdom, China, Spain, and Canada).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [31] Van Calster, 2014, Evaluating the risk of ovarian cancer before surgery using the ADNEX model to differentiate between benign, borderline, early and advanced stage invasive, and secondary metastatic tumours: prospective multicentre diagnostic study, BMJ source
Not checked in the free run.
May combine two claims.
Premisecitation§ Case study: external validation of a diagnostic model for ovarian cancer · p. 3ADNEX can inform decisions regarding type of surgery (advanced vs conservative) for patients examined at an oncology centre or regarding referral to an oncology centre for patients examined elsewhere.
“The model can inform decisions regarding the type of surgery (advanced vs conservative) for patients examined at an oncology centre or regarding referral to an oncology centre for patients examined elsewhere. 32”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [32] Landolfo, 2024, Comparison of the ADNEX and ROMA risk prediction models for the diagnosis of ovarian cancer: a multicentre external validation in patients who underwent surgery, Br J Cancer source
Not checked in the free run.
May combine two claims.
Premisecitation§ Calibration · p. 6Estimated probabilities with too much spread are on average too close to 0 and 1 (calibration slope < 1), whereas estimated probabilities with too little spread are on average too close to the prevalence (calibration slope > 1).
“Estimated probabilities with too much spread are on average too close to 0 and 1 (slope < 1), whereas estimated probabilities with too little spread are on average too close to the prevalence (slope > 1).”
Quote in the paperSubstantial claim0 of 2 sources checked- cites [52] Van Calster, 2016, A calibration hierarchy for risk models was defined: from utopia to empirical data, J Clin Epidemiol source
Not checked in the free run.
- cites [53] Stevens, 2020, Validation of clinical prediction models: what does the “calibration slope” really measure?, J Clin Epidemiol source
Not checked in the free run.
May combine two claims.
Interpretationreasoning§ Case study: external validation of a diagnostic model for ovarian cancer · p. 3Logistic recalibration is a rank-preserving method, and the ranking of patients based on the estimated probability of malignancy remains the same before and after updating.
“This method is thus a rank-preserving method, and the ranking of patients based on the estimated probability of malignancy remains the same before and after updating.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S2 (checkable).
Premisenone given§ Panel: Defining a decision threshold · p. 3The weight of the consequences of using a model to support a decision might vary by the nature and effects of the intervention, the health-care system, or by clinician and patient.
“The weight of these consequences might vary by the nature and effects of the intervention, the health-care system, or by clinician and patient.”
Quote in the paperNot a substantial claim- Rests on an assumption: The primary aim of most predictive AI models in medical practice is to support subsequent decision making.
May combine two claims.
Premisecitation§ Calibration · p. 6ECE, ECI, and ICI depend on the grouping or smoothing methods used and have issues with statistical consistency.
“Further, ECE, ECI, and ICI depend on the grouping or smoothing methods used and have issues with statistical consistency.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [62] Arrieta-Ibarra, 2022, Metrics of calibration for probabilistic predictions, J Mach Learn Res
Not checked in the free run.
Probably not a substantial claim: may not pass S2 (checkable). May combine two claims.
Interpretationreasoning§ Clear focus on statistical or decision-analytical evaluation · p. 2It is not appropriate to cite good discrimination and calibration or conclude that a model can be used to aid decisions about ovarian surgery.
“it is not appropriate to cite, for example, good discrimination and calibration or conclude that a model can be used to aid decisions about ovarian surgery.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Premisecitation§ Case study: external validation of a diagnostic model for ovarian cancer · p. 3There were 434 women with a malignant tumour (prevalence 49%).
“There were 434 women with a malignant tumour (prevalence 49%). 32”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [32] Landolfo, 2024, Comparison of the ADNEX and ROMA risk prediction models for the diagnosis of ovarian cancer: a multicentre external validation in patients who underwent surgery, Br J Cancer source
Not checked in the free run.
Classified as probably not a substantial claim.
Premisenone given§ Panel: Defining a decision threshold · p. 3Often, a threshold is chosen by optimising a statistical measure such as the Youden index.
“Often, however, a threshold is chosen by optimising a statistical measure such as the Youden index (sensitivity + specificity -1).”
Quote in the paperSubstantial claim- Rests on an assumption: The primary aim of most predictive AI models in medical practice is to support subsequent decision making.
May combine two claims.
Premisecitation§ Overall performance · p. 6Discrimination slope and mean absolute prediction error are improper.
“discrimination slope and mean absolute prediction error are improper.”
Quote in the paperNot a substantial claim0 of 3 sources checked- cites [26] Buja
Not checked in the free run.
- cites [27] Gneiting, 2007, Strictly proper scoring rules, prediction, and estimation, J Am Stat Assoc source
Not checked in the free run.
- cites [71] Van Houwelingen, 2012
Not checked in the free run.
Probably not a substantial claim: may not pass S2 (checkable), S3 (load-bearing), S4 (based). May combine two claims.
Premisenone given§ Discrimination · p. 5Although true negatives might be highly irrelevant for selected non-medical applications, such errors are generally important in medical applications.
“Although true negatives might be highly irrelevant for selected non-medical applications, such errors are generally important in medical applications.”
Quote in the paperNot a substantial claimMay combine two claims.
Interpretationcitation§ Discrimination · p. 5Although discriminatory ability is essential for predictive AI, AUROC alone cannot be used to identify a model as good or useful.
“Nevertheless, although discriminatory ability is essential for predictive AI, AUROC alone cannot be used to identify a model as good or useful. 51”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [51] de Hond, 2022, Interpreting area under the receiver operating characteristic curve, Lancet Digit Health source
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing).
Premisecitation§ Case study: external validation of a diagnostic model for ovarian cancer · p. 3Logistic recalibration is similar to Platt scaling, a well known method in machine learning to improve the calibration of predictions.
“This method is similar to Platt scaling, a well known method in machine learning to improve the calibration of predictions. 34,35”
Quote in the paperNot a substantial claim0 of 2 sources checked- cites [34] Ojeda, 2023, Calibrating machine learning approaches for probability estimation: a comprehensive comparison, Stat Med source
Not checked in the free run.
- cites [35] Platt, 1999, Probabilistic outputs for support vector machines and comparison to regularized likelihood methods
Not checked in the free run.
May combine two claims.
Premisecitation§ Case study: external validation of a diagnostic model for ovarian cancer · p. 3The TransIOTA study externally validated ADNEX for its ability to distinguish benign from malignant tumours, using data from 894 women recruited between 2015 and 2019 in one secondary and five tertiary care centres in four countries.
“The TransIOTA study externally validated ADNEX for its ability to distinguish benign from malignant tumours, using data from 894 women recruited between 2015 and 2019 in one secondary and five tertiary care centres in four countries (Belgium, Italy, Czech Republic, and United Kingdom).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [32] Landolfo, 2024, Comparison of the ADNEX and ROMA risk prediction models for the diagnosis of ovarian cancer: a multicentre external validation in patients who underwent surgery, Br J Cancer source
Not checked in the free run.
Probably not a substantial claim: may not pass S4 (based).
Premisenone given§ Department of Development · p. 2In biomedical applications, the consequences of a false negative are almost always different from the consequences of a false positive.
“In biomedical applications, the consequences of a false negative (for instance, not referring a woman with ovarian malignancy for advanced surgery) are almost always different from the consequences of a false positive (referring a woman with a benign tumour for advanced surgery).”
Quote in the paperNot a substantial claimMay combine two claims.
Interpretationreasoning§ Discrimination · p. 5AUPRC and pAUROC mix statistical performance with aspects of clinical utility without following decision-analytical principles.
“AUPRC and pAUROC mix statistical performance with aspects of clinical utility without following decision-analytical principles.”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Premisecitation§ Discrimination · p. 4For binary outcomes, the C-statistic is equal to area under the receiver operating characteristic curve (AUROC).
“For binary outcomes, the C-statistic is equal to area under the receiver operating characteristic curve (AUROC). 37,38”
Quote in the paperNot a substantial claim0 of 2 sources checked- cites [37] Bradley, 1997, The use of the area under the ROC curve in the evaluation of machine learning algorithms, Pattern Recognit source
Not checked in the free run.
- cites [38] Verbakel, 2020, ROC curves for clinical prediction models part 1. ROC plots showed no added value above the AUC when evaluating the performance of clinical prediction models, J Clin Epidemiol source
Not checked in the free run.
May combine two claims.
Premisecitation§ Overall performance · p. 6Loglikelihood, logloss, and Brier score are strictly proper.
“Loglikelihood, logloss, and Brier score are strictly proper”
Quote in the paperNot a substantial claim0 of 3 sources checked- cites [26] Buja
Not checked in the free run.
- cites [27] Gneiting, 2007, Strictly proper scoring rules, prediction, and estimation, J Am Stat Assoc source
Not checked in the free run.
- cites [71] Van Houwelingen, 2012
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing).
Premisecitation§ Calibration · p. 5Calibration approaches can be classified into three increasingly stringent levels, labelled as mean, weak, and moderate calibration.
“These approaches can be classified into three increasingly stringent levels, labelled as mean, weak, and moderate calibration. 52”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [52] Van Calster, 2016, A calibration hierarchy for risk models was defined: from utopia to empirical data, J Clin Epidemiol source
Not checked in the free run.
May combine two claims.
Interpretationcitation§ Discrimination · p. 4AUROC, AUPRC, and pAUROC are semi-proper, because these rank-based measures are invariant to monotonic transformations of probability estimates.
“AUROC, AUPRC, and pAUROC are semi-proper, because these rank-based measures are invariant to monotonic transformations of probability estimates. 48”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [48] Pepe, 2015, The Net Reclassification Index (NRI): a misleading measure of prediction improvement even with independent test data sets, Stat Biosci source
Not checked in the free run.
Probably not a substantial claim: may not pass S4 (based). May combine two claims.
Premisenone given§ Panel: Defining a decision threshold · p. 3When maximising the Youden index, sensitivity and specificity are considered equally important; this is rarely the case in medicine.
“When maximising the Youden index, sensitivity and specificity are considered equally important; this is rarely the case in medicine.”
Quote in the paperNot a substantial claim- Rests on an assumption: The primary aim of most predictive AI models in medical practice is to support subsequent decision making.
Classified as probably not a substantial claim. May combine two claims.
Premisenone given§ Clear focus on statistical or decision-analytical evaluation · p. 2The first four performance domains focus on different aspects of statistical performance, whereas the clinical utility domain focuses on decision-analytical performance.
“The fi rst four performance domains (appendix p 2) focus on different aspects of statistical performance, whereas the clinical utility domain focuses on decision-analytical performance.”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S2 (checkable).
Interpretationreasoning§ Discussion · p. 8Improper measures might mislead researchers instead of clarifying the performance of a model.
“Improper measures might mislead researchers instead of clarifying the performance of a model.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S4 (based). May combine two claims.
Premisenone given§ Discussion · p. 9Classification accuracy, balanced accuracy, Youden index, DOR, kappa, F1, and MCC are improper at clinically relevant decision thresholds; in addition, some measures are hard to interpret.
“These measures are improper at clinically relevant decision thresholds; in addition, some measures are hard to interpret.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S2 (checkable), S3 (load-bearing), S4 (based).
Premisenone given§ Discussion · p. 9Displaying the distribution of risk estimates for each outcome category provides valuable insights into a model's behaviour.
“Displaying the distribution of the risk estimates for each outcome category provides valuable insights into a model's behaviour.”
Quote in the paperNot a substantial claimMay combine two claims.
Interpretationnone given§ Discussion · p. 8F1 is the only measure violating both characteristics: being improper and not having a clear focus on either statistical or decision-analytical performance.
“Remarkably, F1 is the only measure violating both characteristics.”
Quote in the paperNot a substantial claimMay combine two claims.
Premisecitation§ Clinical utility · p. 7Net benefit and standardised net benefit are semi-proper; the probability estimates below the threshold can be anything as long as they are below the threshold, and the same goes for probability estimates above the threshold.
“Net benefit and standardised net benefit are semi-proper; the probability estimates below the threshold can be anything as long as they are below the threshold, and the same goes for probability estimates above the threshold.”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [48] Pepe, 2015, The Net Reclassification Index (NRI): a misleading measure of prediction improvement even with independent test data sets, Stat Biosci source
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing).
Premisenone given§ Overall performance · p. 6All discussed overall performance measures have a focus on statistical performance.
“All discussed overall measures have a focus on statistical performance.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S2 (checkable).
Interpretationreasoning§ Discussion · p. 9Discrimination and calibration aid the modeller and clinician to understand how a model can be improved.
“Discrimination and calibration aid the modeller and clinician to understand how a model can be improved.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing), S4 (based).
Premisenone given§ Discussion · p. 9ROC and PR curves provide limited additional information over AUROC.
“These plots provide limited additional information over AUROC.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Premisenone given§ Clinical utility · p. 7Expected cost is semi-proper because it is insensitive to rank-preserving transformations of the probabilities.
“Expected cost is semi-proper because it is insensitive to rank-preserving transformations of the probabilities.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
Premisecitation§ Clinical utility · p. 7Standardised net benefit equals net benefit divided by prevalence, and its maximum value is 1.
“Standardised net benefit equals net benefit divided by prevalence, and its maximum value is 1.”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [84] Kerr, 2016, Assessing the clinical impact of risk prediction models with decision curves: guidance for correct interpretation and appropriate use, J Clin Oncol source
Not checked in the free run.
May combine two claims.
Premisecitation§ Discussion · p. 9Calibration intercept and calibration slope are hard to interpret and provide a partial assessment of calibration; during internal validation, calibration slope can be used to gauge overfitting.
“These measures are hard to interpret and provide a partial assessment of calibration; during internal validation, calibration slope can be used to gauge overfitting.”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [66] Kattan, 2018, The index of prediction accuracy: an intuitive measure useful for evaluating risk prediction models, Diagn Progn Res source
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing).
Premisecitation§ Classification measures · p. 7A limitation of ROC and PR curves is that the thresholds are not easily visible.
“A limitation of these plots is that the thresholds are not easily visible (figure 1).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [38] Verbakel, 2020, ROC curves for clinical prediction models part 1. ROC plots showed no added value above the AUC when evaluating the performance of clinical prediction models, J Clin Epidemiol source
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing), S4 (based).
Premisereasoning§ Discussion · p. 9Sensitivity and specificity are largely theoretical as they condition on the predicted outcome.
“However, these measures are largely theoretical as they condition on the predicted outcome.”
Quote in the paperNot a substantial claimMay combine two claims.
Premisecitation§ Clinical utility · p. 7Setting misclassification costs is not straightforward, and disagreements can occur about what the costs should be.
“Setting misclassification costs is not straightforward, and disagreements can occur about what the costs should be (appendix p 13).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [85] Vickers, 2019, A simple, step-by-step guide to interpreting decision curve analysis, Diagn Progn Res source
Not checked in the free run.
May combine two claims.
Premisenone given§ Discussion · p. 9Discrimination slope and MAPE are improper; values can be better for incorrect models than for the correct model.
“These measures are improper; ie, values can be better for incorrect models than for the correct model.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing), S4 (based). May combine two claims.
Premisenone given§ Discussion · p. 9AUROC quantifies discrimination, which is a key component of statistical model performance.
“This measure quantifies discrimination, which is a key component of statistical model performance.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Premisecitation§ Clinical utility · p. 7Net benefit sets the decision threshold based on the misclassification costs, following the classic connection between both.
“Net benefit sets the decision threshold based on the misclassification costs, following the classic connection between both.”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [18] Pauker, 1975, Therapeutic decision making: a cost-benefit analysis, N Engl J Med source
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing).
Premisecitation§ Clinical utility · p. 7Expected cost searches for the decision threshold that minimises cost given the misclassification costs.
“In contrast to net benefit, expected cost searches for the decision threshold that minimises cost given the misclassification costs.”
Quote in the paperNot a substantial claim0 of 4 sources checked- cites [86] Margineantu, 2000, Bootstrap methods for the cost-sensitive evaluation of classifiers
Not checked in the free run.
- cites [87] Ferrer, 2022, Analysis and comparison of classification metrics, arXiv
Not checked in the free run.
- cites [88] Provost, 2001, Robust classification for imprecise environments, Mach Learn source
Not checked in the free run.
- cites [89] Van Calster, 2015, Calibration of risk prediction models: impact on decision-analytic performance, Med Decis Making source
Not checked in the free run.
Probably not a substantial claim: may not pass S2 (checkable), S3 (load-bearing), S4 (based).
Interpretationnone given§ Discussion · p. 9Poor discrimination indicates that other predictors facilitating improved distinction between individuals with and without the event could be selected.
“Poor discrimination indicates that other predictors facilitating improved distinction between individuals with and without the event could be selected.”
Quote in the paperNot a substantial claimMay combine two claims.
Premisecitation§ Clinical utility · p. 7Miscalibration of the model might be reflected in the decision threshold at which expected cost is minimised, whereas net benefit fixes the threshold such that miscalibration reduces the net benefit value.
“Miscalibration of the model might thus be reflected in the decision threshold at which expected cost is minimised, whereas net benefit fi xes the threshold such that miscalibration reduces the net benefit value.”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [89] Van Calster, 2015, Calibration of risk prediction models: impact on decision-analytic performance, Med Decis Making source
Not checked in the free run.
Probably not a substantial claim: may not pass S4 (based). May combine two claims.
Premisenone given§ Discussion · p. 9AUPRC and pAUROC attempt to move beyond a statistical assessment but violate decision-analytical principles.
“These measures attempt to move beyond a statistical assessment but violate decision-analytical principles.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S4 (based). May combine two claims.
Premisenone given§ Discussion · p. 9ECI, ICI, and ECE summarise calibration plots, concealing the nature and direction of miscalibration, and struggle with statistical consistency.
“These measures summarise calibration plots, concealing the nature and direction of miscalibration, and struggle with statistical consistency.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing), S4 (based). May combine two claims.
Premisenone given§ Discussion · p. 9The O:E ratio is interpretable but provides only a partial assessment of calibration; it is often 1 or close to 1 during internal validation.
“This measure is interpretable but provides only a partial assessment of calibration; O:E ratio is often 1 or close to 1 during internal validation.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Premisereasoning§ Classification measures · p. 6MCC has no intuitive interpretation.
“Similar to F1, MCC has no intuitive interpretation.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Premisenone given§ Discussion · p. 9PPV and NPV are highly practical measures because they condition on the classification.
“PPV and NPV are highly practical measures because they condition on the classification.”
Quote in the paperNot a substantial claimClassified as probably not a substantial claim. May combine two claims.
Interpretationnone given§ Discussion · p. 9Overall performance measures combine discrimination and calibration performance, making them less informative than separate assessments of discrimination and calibration performance.
“Overall performance measures combine discrimination and calibration performance, making them less informative than separate assessments of discrimination and calibration performance.”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S4 (based). May combine two claims.
Interpretationnone given§ Discussion · p. 9PPV in combination with NPV, or sensitivity in combination with specificity, are improper when used alone.
“These measures are improper when used alone.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S2 (checkable). May combine two claims.
Interpretationnone given§ Discussion · p. 9NB or standardised NB (with a decision curve) and EC (with a cost curve) are important measures to quantify to what extent better decisions are made.
“NB or standardised NB (with a decision curve) and EC (with a cost curve) Recommended Important measures to quantify to what extent better decisions are made.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S2 (checkable). May combine two claims.
Interpretationnone given§ Discussion · p. 10Class imbalance is related to the target population as an epidemiological feature of the data, whereas misclassification costs are clinical concepts that relate to the context of decision making.
“Class imbalance is related to the target population as an epidemiological feature of the data, whereas misclassification costs are clinical concepts that relate to the context of decision making.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S2 (checkable), S3 (load-bearing), S4 (based).
Interpretationnone given§ Discussion · p. 10The principles also hold for other types of outcomes, such as nominal, ordinal, time-to-event, or competing risk outcomes.
“Nevertheless, the principles also hold for other types of outcomes, such as nominal, ordinal, time-to-event, or competing risk outcomes.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing), S4 (based).
Interpretationnone given§ Discussion · p. 9For well-developed models, an O:E ratio close to 1 is expected.
“we would expect an O:E ratio close to 1 for welldeveloped models.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Interpretationnone given§ Discussion · p. 10Competing models can be evaluated using the same core set of measures and visualisations.
“Although competing models can be evaluated using the same core set of measures and visualisations, proper overall measures become more interesting for tasks such as model selection and comparison.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S4 (based).
Interpretationnone given§ Discussion · p. 9Decision curves of NB allow one to show potential clinical utility at various clinically relevant decision thresholds relative to default decisions (and competing models).
“Decision curves of NB allow one to show potential clinical utility at various clinically relevant decision thresholds relative to default decisions (and competing models).”
Quote in the paperNot a substantial claimClassified as probably not a substantial claim.
Interpretationnone given§ Discussion · p. 10Adequate sample size is important to evaluate performance with sufficient precision.
“First, adequate sample size is important to evaluate performance with sufficient precision.”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Premisecitation§ Discussion · p. 10Previous recommendations were to include at least 100 to 200 individuals in the smallest outcome category.
“Previous recommendations were to include at least 100 to 200 individuals in the smallest outcome category.”
Quote in the paperNot a substantial claim0 of 2 sources checked- cites [52] Van Calster, 2016, A calibration hierarchy for risk models was defined: from utopia to empirical data, J Clin Epidemiol source
Not checked in the free run.
- cites [99] Collins, 2016, Sample size considerations for the external validation of a multivariable prognostic model: a resampling study, Stat Med source
Not checked in the free run.
Probably not a substantial claim: may not pass S2 (checkable), S3 (load-bearing).
Interpretationcitation§ Discussion · p. 9Miscalibration is often not just a problem of the model but a sign that we need to improve our understanding of the various contexts in which the model is validated and used.
“Miscalibration is often not just a problem of the model but a sign that we need to improve our understanding of the various contexts in which the model is validated and used.”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [91] Van Calster, 2023, There is no such thing as a validated prediction model, BMC Med source
Not checked in the free run.
Probably not a substantial claim: may not pass S2 (checkable), S3 (load-bearing), S4 (based).
Interpretationnone given§ Discussion · p. 10Proper overall measures become more interesting for tasks such as model selection and comparison.
“Although competing models can be evaluated using the same core set of measures and visualisations, proper overall measures become more interesting for tasks such as model selection and comparison.”
Quote in the paperNot a substantial claim
The authors state this as an assumption.
Using a decision threshold of 0.1 for probability of malignancy assumes that the medical benefit of advanced surgery on a malignant tumour is nine times greater than the harm of unnecessary advanced surgery in individuals with a benign tumour.
“Hence, using this threshold assumes that the medical benefit of advanced surgery on a malignant tumour is nine times greater than the harm of unnecessary advanced surgery in individuals with a benign tumour. 18”
The paper relies on this without support.
The primary aim of most predictive AI models in medical practice is to support subsequent decision making.
“The primary aim of most predictive AI models in medical practice is to support subsequent decision making.”
The authors state this as an assumption.
The range of reasonable decision thresholds is 0.05 to 0.40 (normalised cost of false negatives between 0.60 and 0.95).
“We further assume that the range of reasonable thresholds is 0 ⋅ 05 to 0 ⋅ 40 (normalised cost of false negatives between 0 ⋅ 60 and 0 ⋅ 95).”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Recalibrated logloss conflicts with loglikelihood
MinorThe paper defines logloss as negative loglikelihood. After recalibration, a loglikelihood of −337 therefore implies a logloss of 337, not the reported 377. The reported logloss also falls outside its stated 95% confidence interval of 307 to 368 and would contradict the claim that all strictly proper measures improved.
“| Logloss or cross entropy | ++ | + | 370 (334 to 407) | 377 (307 to 368) |”
“| Loglikelihood | ++ | + | -370 (-407 to -334) | -337 (-368 to -307) |”
AUPRC confidence-interval upper bound differs between text and table
MinorThe text gives an AUPRC 95% confidence-interval upper bound of 0.91, whereas the table gives 0.921, which rounds to 0.92 at the precision used in the text.
“an AUPRC of 0 ⋅ 89 (95% CI 0 ⋅ 86-0 ⋅ 91)”
“| AUPRC or AP | + | - | 0 ⋅ 895 (0 ⋅ 862 to 0 ⋅ 921) | 0 ⋅ 895 (0 ⋅ 862 to 0 ⋅ 921) |”
Cites
A Coefficient of Agreement for Nominal Scales
Cohen, J. (1960) · Educational and Psychological Measurement · doi:10.1177/001316446002000104 · Cited by 42,398 · see citing works
The use of the area under the ROC curve in the evaluation of machine learning algorithms
Bradley, A. P. (1997) · Pattern Recognition · doi:10.1016/s0031-3203(96)00142-2 · Cited by 7,217 · see citing works
Pencina, M. J., D' Agostino, R. B., D' Agostino, R. B., & Vasan, R. S. (2008) · Statistics in Medicine · doi:10.1002/sim.2929 · Cited by 6,493 · see citing works
Decision curve analysis: a novel method for evaluating prediction models
Vickers, A. J., & Elkin, E. B. (2006) · Medical Decision Making · doi:10.1177/0272989x06295361 · Cited by 6,341 · see citing works
Self-citationChicco, D., & Jurman, G. (2020) · BMC Genomics · doi:10.1186/s12864-019-6413-7 · Cited by 6,143 · see citing works
A note on a general definition of the coefficient of determination
NAGELKERKE, N. J. D. (1991) · Biometrika · doi:10.1093/biomet/78.3.691 · Cited by 5,927 · see citing works
Strictly Proper Scoring Rules, Prediction, and Estimation
Gneiting, T., & Raftery, A. E. (2007) · Journal of the American Statistical Association · doi:10.1198/016214506000001437 · Cited by 5,793 · see citing works
Saito, T., & Rehmsmeier, M. (2015) · PLOS ONE · doi:10.1371/journal.pone.0118432 · Cited by 5,309 · see citing works
Assessing the Performance of Prediction Models: A Framework for Traditional and Novel Measures
Steyerberg, E. W., Vickers, A. J., Cook, N. R., Gerds, T., Gonen, M., Obuchowski, N., Pencina, M. J., & Kattan, M. W. (2010) · Epidemiology · doi:10.1097/ede.0b013e3181c30fb2 · Cited by 5,170 · see citing works
Self-citationMoons, K. G. M., Altman, D. G., Reitsma, J. B., Ioannidis, J. P. A., Macaskill, P., Steyerberg, E. W., Vickers, A. J., Ransohoff, D. F., & Collins, G. S. (2015) · Annals of Internal Medicine · doi:10.7326/m14-0698 · Cited by 5,147 · see citing works
Self-citationCollins, G. S., Moons, K. G. M., Dhiman, P., Riley, R. D., Beam, A. L., Van Calster, B., Ghassemi, M., Liu, X., Reitsma, J. B., van Smeden, M., et al. (2024) · BMJ · doi:10.1136/bmj-2023-078378 · Cited by 4,718 · see citing works
Self-citationAUC: A misleading measure of the performance of predictive distribution models
Lobo, J. M., Jiménez‐Valverde, A., & Real, R. (2008) · Global Ecology and Biogeography · doi:10.1111/j.1466-8238.2007.00358.x · Cited by 3,499 · see citing works
Calibration: the Achilles heel of predictive analytics
On behalf of Topic Group ‘Evaluating diagnostic tests and prediction models’ of the STRATOS initiative, Van Calster, B., McLernon, D. J., van Smeden, M., Wynants, L., & Steyerberg, E. W. (2019) · BMC Medicine · doi:10.1186/s12916-019-1466-7 · Cited by 2,650 · see citing works
Self-citationAssessing the accuracy of prediction algorithms for classification: an overview
Baldi, P., Brunak, S., Chauvin, Y., Andersen, C. A. F., & Nielsen, H. (2000) · Bioinformatics · doi:10.1093/bioinformatics/16.5.412 · Cited by 2,111 · see citing works
Robust classification for imprecise environments
Provost, F., & Fawcett, T. (2001) · Machine Learning · doi:10.1023/a:1007601015854 · Cited by 1,250 · see citing works
A simple, step-by-step guide to interpreting decision curve analysis
Vickers, A. J., van Calster, B., & Steyerberg, E. W. (2019) · Diagnostic and Prognostic Research · doi:10.1186/s41512-019-0064-7 · Cited by 1,174 · see citing works
Self-citationA calibration hierarchy for risk models was defined: from utopia to empirical data
Van Calster, B., Nieboer, D., Vergouwe, Y., De Cock, B., Pencina, M. J., & Steyerberg, E. W. (2016) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2015.12.005 · Cited by 910 · see citing works
Self-citationChicco, D., Tötsch, N., & Jurman, G. (2021) · BioData Mining · doi:10.1186/s13040-021-00244-z · Cited by 893 · see citing works
An experimental comparison of performance measures for classification
Ferri, C., Hernández-Orallo, J., & Modroiu, R. (2009) · Pattern Recognition Letters · doi:10.1016/j.patrec.2008.08.010 · Cited by 889 · see citing works
Evaluation of clinical prediction models (part 1): from development to external validation
Collins, G. S., Dhiman, P., Ma, J., Schlussel, M. M., Archer, L., Van Calster, B., Harrell, F. E., Martin, G. P., Moons, K. G. M., van Smeden, M., et al. (2024) · BMJ · doi:10.1136/bmj-2023-074819 · Cited by 798 · see citing works
Self-citationCoefficients of Determination for Multiple Logistic Regression Analysis
Menard, S. (2000) · The American Statistician · doi:10.1080/00031305.2000.10474502 · Cited by 739 · see citing works
Kerr, K. F., Brown, M. D., Zhu, K., & Janes, H. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.5654 · Cited by 697 · see citing works
Self-citationCollins, G. S., Ogundimu, E. O., & Altman, D. G. (2016) · Statistics in Medicine · doi:10.1002/sim.6787 · Cited by 665 · see citing works
Leening, M. J. G., Vedder, M. M., Witteman, J. C. M., Pencina, M. J., & Steyerberg, E. W. (2014) · Annals of Internal Medicine · doi:10.7326/m13-1522 · Cited by 594 · see citing works
Self-citationTwo further applications of a model for binary regression
COX, D. R. (1958) · Biometrika · doi:10.1093/biomet/45.3-4.562 · Cited by 556 · see citing works
Metrics reloaded: recommendations for image analysis validation
Maier‐Hein, L., Reinke, A., Godau, P., Tizabi, M. D., Buettner, F., Christodoulou, E., Glocker, B., Isensee, F., Kleesiek, J., Kozubek, M., et al. (2024) · Nature Methods · doi:10.1038/s41592-023-02151-z · Cited by 539 · see citing works
Self-citationSecond opinion needed: Communicating uncertainty in medical machine learning
Kompa, B., Snoek, J., & Beam, A. L. (2021) · npj Digital Medicine · doi:10.1038/s41746-020-00367-3 · Cited by 514 · see citing works
Van Calster, B., Van Hoorde, K., Valentin, L., Testa, A. C., Fischerova, D., Van Holsbeke, C., Savelli, L., Franchi, D., Epstein, E., Kaijser, J., et al. (2014) · BMJ · doi:10.1136/bmj.g5920 · Cited by 510 · see citing works
Therapeutic decision making: a cost-benefit analysis
Pauker, S. G., & Kassirer, J. P. (1975) · New England Journal of Medicine · doi:10.1056/nejm197507312930505 · Cited by 507 · see citing works
Interpreting area under the receiver operating characteristic curve
de Hond, A. A. H., Steyerberg, E. W., & van Calster, B. (2022) · The Lancet Digital Health · doi:10.1016/s2589-7500(22)00188-1 · Cited by 503 · see citing works
Self-citationExternal correspondence: Decompositions of the mean probability score
Yates, J. (1982) · Organizational Behavior and Human Performance · doi:10.1016/0030-5073(82)90237-9 · Cited by 466 · see citing works
Causal inference and counterfactual prediction in machine learning for actionable healthcare
Prosperi, M., Guo, Y., Sperrin, M., Koopman, J. S., Min, J. S., He, X., Rich, S., Wang, M., Buchan, I. E., & Bian, J. (2020) · Nature Machine Intelligence · doi:10.1038/s42256-020-0197-y · Cited by 459 · see citing works
Minimum sample size for external validation of a clinical prediction model with a binary outcome
Riley, R. D., Debray, T. P. A., Collins, G. S., Archer, L., Ensor, J., van Smeden, M., & Snell, K. I. E. (2021) · Statistics in Medicine · doi:10.1002/sim.9025 · Cited by 400 · see citing works
Self-citationOzenne, B., Subtil, F., & Maucort-Boulch, D. (2015) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2015.02.010 · Cited by 379 · see citing works
Calibration of Risk Prediction Models: Impact on Decision-Analytic Performance
Van Calster, B., & Vickers, A. J. (2015) · Medical Decision Making · doi:10.1177/0272989x14547233 · Cited by 371 · see citing works
Austin, P. C., & Steyerberg, E. W. (2014) · Statistics in Medicine · doi:10.1002/sim.5941 · Cited by 362 · see citing works
Self-citationPartial AUC Estimation and Regression
Dodd, L. E., & PEPE, M. S. (2003) · Biometrics · doi:10.1111/1541-0420.00071 · Cited by 339 · see citing works
Austin, P. C., & Steyerberg, E. W. (2019) · Statistics in Medicine · doi:10.1002/sim.8281 · Cited by 311 · see citing works
Self-citationThere is no such thing as a validated prediction model
Van Calster, B., Steyerberg, E. W., Wynants, L., & van Smeden, M. (2023) · BMC Medicine · doi:10.1186/s12916-023-02779-w · Cited by 286 · see citing works
A framework for meta-analysis of prediction model studies with binary and time-to-event outcomes
Debray, T. P., Damen, J. A., Riley, R. D., Snell, K., Reitsma, J. B., Hooft, L., Collins, G. S., & Moons, K. G. (2019) · Statistical Methods in Medical Research · doi:10.1177/0962280218785504 · Cited by 278 · see citing works
Self-citationA note on using the F-measure for evaluating record linkage algorithms
Hand, D., & Christen, P. (2018) · Statistics and Computing · doi:10.1007/s11222-017-9746-6 · Cited by 247 · see citing works
Clinical prediction models: diagnosis versus prognosis
van Smeden, M., Reitsma, J. B., Riley, R. D., Collins, P. G. S., & Moons, K. G. M. (2021) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2021.01.009 · Cited by 241 · see citing works
Self-citationA review of the F-measure: its history, properties, criticism, and alternatives
Christen, P., Hand, D. J., & Kirielle, N. (2024) · ACM Computing Surveys · doi:10.1145/3606367 · Cited by 236 · see citing works
Nattino, G., Pennell, M. L., & Lemeshow, S. (2020) · Biometrics · doi:10.1111/biom.13249 · Cited by 229 · see citing works
Assessing the incremental value of diagnostic and prognostic markers: a review and illustration
Steyerberg, E. W., Pencina, M. J., Lingsma, H. F., Kattan, M. W., Vickers, A. J., & Van Calster, B. (2012) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2011.02562.x · Cited by 219 · see citing works
Self-citationThree myths about risk thresholds for prediction models
on behalf of the Topic Group ‘Evaluating diagnostic tests and prediction models’ of the STRATOS initiative, Wynants, L., van Smeden, M., McLernon, D. J., Timmerman, D., Steyerberg, E. W., & Van Calster, B. (2019) · BMC Medicine · doi:10.1186/s12916-019-1425-3 · Cited by 213 · see citing works
Self-citationStability of clinical prediction models developed using statistical or machine learning methods
Riley, R. D., & Collins, G. S. (2023) · Biometrical Journal · doi:10.1002/bimj.202200302 · Cited by 211 · see citing works
Self-citationHilden, J., & Gerds, T. A. (2013) · Statistics in Medicine · doi:10.1002/sim.5804 · Cited by 200 · see citing works
Pepe, M. S., Fan, J., Feng, Z., Gerds, T., & Hilden, J. (2015) · Statistics in Biosciences · doi:10.1007/s12561-014-9118-0 · Cited by 191 · see citing works
Assessing the Performance of Classification Methods
Hand, D. J. (2012) · International Statistical Review · doi:10.1111/j.1751-5823.2012.00183.x · Cited by 177 · see citing works
External validation of AI models in health should be replaced with recurring local validation
Youssef, A., Pencina, M., Thakur, A., Zhu, T., Clifton, D., & Shah, N. H. (2023) · Nature Medicine · doi:10.1038/s41591-023-02540-z · Cited by 170 · see citing works
Carrington, A., Fieguth, P., Qazi, H. A., Holzinger, A., Chen, H., Mayr, F., & Manuel, D. G. (2020) · BMC Medical Informatics and Decision Making · doi:10.1186/s12911-019-1014-6 · Cited by 157 · see citing works
The index of prediction accuracy: an intuitive measure useful for evaluating risk prediction models
Kattan, M. W., & Gerds, T. A. (2018) · Diagnostic and Prognostic Research · doi:10.1186/s41512-018-0029-2 · Cited by 149 · see citing works
Evidence of questionable research practices in clinical prediction models
White, N. M., Parsons, R., Collins, P. G. S., & Barnett, A. G. (2023) · BMC Medicine · doi:10.1186/s12916-023-03048-6 · Cited by 149 · see citing works
Self-citationValidation of clinical prediction models: what does the “calibration slope” really measure?
Stevens, R. J., & Poppe, K. K. (2020) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2019.09.016 · Cited by 146 · see citing works
Dhiman, P., Ma, J., Andaur Navarro, C. L., Speich, B., Bullock, G., Damen, J. A. A., Hooft, L., Kirtley, S., Riley, R. D., Van Calster, B., et al. (2022) · BMC Medical Research Methodology · doi:10.1186/s12874-022-01577-x · Cited by 140 · see citing works
Verbakel, J. Y., Steyerberg, E. W., Uno, H., De Cock, B., Wynants, L., Collins, G. S., & Van Calster, B. (2020) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2020.01.028 · Cited by 138 · see citing works
Self-citationCaveats and pitfalls of ROC analysis in clinical microarray research (and how to avoid them)
Berrar, D., & Flach, P. (2012) · Briefings in Bioinformatics · doi:10.1093/bib/bbr008 · Cited by 136 · see citing works
Jenkins, D. A., Martin, G. P., Sperrin, M., Riley, R. D., Debray, T. P. A., Collins, G. S., & Peek, N. (2021) · Diagnostic and Prognostic Research · doi:10.1186/s41512-020-00090-3 · Cited by 131 · see citing works
Self-citationPrediction meets causal inference: the role of treatment in clinical prediction models
van Geloven, N., Swanson, S. A., Ramspek, C. L., Luijken, K., van Diepen, M., Morris, T. P., Groenwold, R. H. H., van Houwelingen, H. C., Putter, H., & le Cessie, S. (2020) · European Journal of Epidemiology · doi:10.1007/s10654-020-00636-1 · Cited by 128 · see citing works
Targeted validation: validating clinical prediction models in their intended population and setting
Sperrin, M., Riley, R. D., Collins, P. G. S., & Martin, G. P. (2022) · Diagnostic and Prognostic Research · doi:10.1186/s41512-022-00136-8 · Cited by 115 · see citing works
Self-citationTimmerman, D., Planchamp, F., Bourne, T., Landolfo, C., du Bois, A., Chiva, L., Cibula, D., Concin, N., Fischerova, D., Froyman, W., et al. (2021) · Ultrasound in Obstetrics & Gynecology · doi:10.1002/uog.23635 · Cited by 114 · see citing works
Self-citationPerspectives on validation of clinical predictive algorithms
de Hond, A., Shah, V. B., Kant, I. M. J., CALSTER, B. V., Steyerberg, E. W., & Hernandez‐Boussard, T. (2023) · npj Digital Medicine · doi:10.1038/s41746-023-00832-9 · Cited by 95 · see citing works
Self-citationPeek, N., Arts, D. G. T., Bosman, R. J., van der Voort, P. H. J., & de Keizer, N. F. (2007) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2006.08.011 · Cited by 92 · see citing works
Choodari‐Oskooei, B., Royston, P. J., & Parmar, M. (2011) · Statistics in Medicine · doi:10.1002/sim.4242 · Cited by 91 · see citing works
A spline-based tool to assess and visualize the calibration of multiclass risk predictions
Van Hoorde, K., Van Huffel, S., Timmerman, D., Bourne, T., & Van Calster, B. (2015) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2014.12.016 · Cited by 85 · see citing works
Self-citationEvaluation of sepsis prediction models before onset of treatment
Kamran, F., Tjandra, D., Heiler, A., Virzi, J., Singh, K., King, J. E., Valley, T. S., & Wiens, J. (2024) · NEJM AI · doi:10.1056/aioa2300032 · Cited by 74 · see citing works
Self-citationCalibrating machine learning approaches for probability estimation: A comprehensive comparison
Ojeda, F. M., Jansen, M. L., Thiéry, A., Blankenberg, S., Weimar, C., Schmid, M., & Ziegler, A. (2023) · Statistics in Medicine · doi:10.1002/sim.9921 · Cited by 71 · see citing works
Deep Learning of Electrocardiograms in Sinus Rhythm From US Veterans to Predict Atrial Fibrillation
Yuan, N., Duffy, G., Dhruva, S. S., Oesterle, A., Pellegrini, C. N., Theurer, J., Vali, M., Heidenreich, P. A., Keyhani, S., & Ouyang, D. (2023) · JAMA Cardiology · doi:10.1001/jamacardio.2023.3701 · Cited by 67 · see citing works
Properties ofR2 statistics for logistic regression
Hu, B., Palta, M., & Shao, J. (2005) · Statistics in Medicine · doi:10.1002/sim.2300 · Cited by 61 · see citing works
The Measurement of Performance in Probabilistic Diagnosis
Habbema, J. D. F., Hilden, J., & Bjerregaard, B. E. (1978) · Methods of Information in Medicine · doi:10.1055/s-0038-1636685 · Cited by 49 · see citing works
Improving the Practice of Classifier Performance Assessment
Adams, N. M., & Hand, D. J. (2000) · Neural Computation · doi:10.1162/089976600300015808 · Cited by 46 · see citing works
Pencina, M. J., Fine, J. P., & D’Agostino, R. B. (2016) · Statistics in Medicine · doi:10.1002/sim.7139 · Cited by 44 · see citing works
Decision curve analysis: confidence intervals and hypothesis testing for net benefit
Vickers, A. J., Claster, B. V., Wynants, L., et al. (2023) · Diagnostic and Prognostic Research · doi:10.1186/s41512-023-00148-y · Cited by 43 · see citing works
Self-citationBarreñada, L., Ledger, A., Dhiman, P., Collins, G., Wynants, L., Verbakel, J. Y., Timmerman, D., Valentin, L., & Van Calster, B. (2024) · BMJ Medicine · doi:10.1136/bmjmed-2023-000817 · Cited by 42 · see citing works
Self-citationHilden, J. (2014) · Epidemiology · doi:10.1097/ede.0000000000000063 · Cited by 33 · see citing works
Threshold-Free Measures for Assessing the Performance of Medical Screening Tests
Yuan, Y., Su, W., & Zhu, M. (2015) · Frontiers in Public Health · doi:10.3389/fpubh.2015.00057 · Cited by 31 · see citing works
Assessing the clinical impact of risk models for opting out of treatment
Kerr, K. F., Brown, M. D., Marsh, T. L., & Janes, H. (2019) · Medical Decision Making · doi:10.1177/0272989x18819479 · Cited by 23 · see citing works
Self-citationInstability of the AUROC of clinical prediction models
van Leeuwen, F. D., Steyerberg, E. W., van Klaveren, D., Wessler, B., Kent, D. M., & van Zwet, E. W. (2025) · Statistics in Medicine · doi:10.1002/sim.70011 · Cited by 19 · see citing works
Self-citationAssessing diagnostic tests by a strictly proper scoring rule
Línnet, K. (1989) · Statistics in Medicine · doi:10.1002/sim.4780080510 · Cited by 16 · see citing works
First things first: risk model performance metrics should reflect the clinical application
Kerr, K. F., & Janes, H. (2017) · Statistics in Medicine · doi:10.1002/sim.7341 · Cited by 16 · see citing works
Self-citationAn improved measure for comparing diagnostic tests
Adams, N. M., & Hand, D. J. (2000) · Computers in Biology and Medicine · doi:10.1016/s0010-4825(99)00025-6 · Cited by 15 · see citing works
Loh, T. P., Lord, S. J., Bell, K., Bohn, M. K., Lim, C. Y., Markus, C., TAIE, H. F., Adeli, K., Lippi, G., Sandberg, S., et al. (2020) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2020.11.003 · Cited by 15 · see citing works
The Importance of Uncertainty and Opt-In v. Opt-Out: Best Practices for Decision Curve Analysis
Kerr, K. F., Marsh, T. L., & Janes, H. E. (2019) · Medical Decision Making · doi:10.1177/0272989x19849436 · Cited by 14 · see citing works
Self-citationLandolfo, C., Ceusters, J., Valentin, L., Froyman, W., Van Gorp, T., Heremans, R., Baert, T., Wouters, R., Vankerckhoven, A., Van Rompuy, A.-S., et al. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02578-x · Cited by 14 · see citing works
Self-citationValue-of-Information Analysis for External Validation of Risk Prediction Models
Sadatsafavi, M., Lee, T. Y., Wynants, L., Vickers, A. J., & Gustafson, P. (2023) · Medical Decision Making · doi:10.1177/0272989x231178317 · Cited by 12 · see citing works
Self-citationZamaray, B., Veld, J. V., Burghgraef, T. A., et al. (2022) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2022.12.008 · Cited by 9 · see citing works
VERIFICATION OF FORECASTS EXPRESSED IN TERMS OF PROBABILITY
BRIER, G. W. (1950) · Monthly Weather Review · doi:10.1175/1520-0493(1950)078
Verification of forecasts expressed in terms of probability
BRIER, G. W. (1950) · Monthly Weather Review · doi:10.1175/1520-0493(1950)078%3c0001:vofeit%3e2.0.co;2
Flagged first, then by citations
Research works printed but not linked: 12
- Hernández-Orallo, 2012, A unified view of performance metrics: translating threshold choice of into expected classification loss, J Mach Learn Res, 13, 2813
- Riley, 2024, Evaluation of clinical prediction models (part 2): how to undertake an external validation study, BMJ, 384
- McDermott, 2024, A closer look at AUROC and AUPRC under class imbalance, Adv Neural Inf Process Syst, 37, 44102
- Błasiok, 2023, Smooth ECE: principled reliability diagrams via kernel smoothing, arXiv
- Arrieta-Ibarra, 2022, Metrics of calibration for probabilistic predictions, J Mach Learn Res, 23, 1
- Vickers, 2016, Net benefit approaches to the evaluation of prediction models, molecular markers, and diagnostic tests, BMJ, 352
- Ferrer, 2022, Analysis and comparison of classification metrics, arXiv
- Wynants, 2020, Prediction models for diagnosis and prognosis of COVID-19: systematic review and critical appraisal, BMJ, 369
- Andaur Navarro, 2021, Risk of bias in studies on prediction models developed using supervised machine learning techniques: systematic review, BMJ, 375
- Debray, 2023, Transparent reporting of multivariable prediction models developed or validated using clustered data (TRIPOD-Cluster): explanation and elaboration, BMJ, 380
- Perez-Lebel, 2022, Beyond calibration: estimating the grouping loss of modern neural networks, arXiv
- Gupta, 2020, Evaluation of machine learning algorithms for predicting readmission after acute myocardial infarction using routinely collected clinical data, Can J Cardiol, 36, 878
Cited by
Sorted by citations
Applications of Artificial Intelligence in Fisheries: From Data to Decisions
Haque, S. A., & Jufaili, S. M. A. (2026) · Big Data and Cognitive Computing · doi:10.3390/bdcc10010019 · Cited by 18 · see citing works
Yang, H. S., Çubukçu, H. C., Ben, F. D., Duan, X., Feng, J., Frans, G., Gruson, D., King, M. C., Nieto, J., Wang, B., et al. (2026) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2025-1322 · Cited by 17 · see citing works
“…performance, classi fi cation, and clinical utility, with area under the receiver operating characteristic curve (AUROC), calibration plots, clinical utility measures (e.g., net bene fi t with decision curve analysis), and outcome-strati fi ed probability distribution as essential elements [30].”
Prospective evaluation of balance and mobility tests as part of the World Falls Guidelines algorithm
Saunders, S., Speechley, M. R., Griffith, L. E., Kuspinar, A., Sibley, K. M., Raina, P., D’Amore, C., Richardson, J. A., Noble, T., & Beauchamp, M. K. (2026) · Age and Ageing · doi:10.1093/ageing/afag028 · Cited by 6 · see citing works
Benitez-Aurioles, J., Wynants, L., Peek, N., et al. (2026) · Diagnostic and Prognostic Research · doi:10.1186/s41512-026-00224-z · Cited by 3 · see citing works
Self-citationPerformance of a Sepsis Prediction Model Across Different Sepsis Definitions
Dutta, S., McMurry, R., Tasi, M. C., Dunham, L. N., McEvoy, D. S., Stump, T., Filbin, M. R., & Rhee, C. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.5599 · Cited by 6 · see citing works
Kourounis, G., Gilbert, S., Knight, S. R., Leal, A., Scully, J. L., Loupy, A., Martin, D., Preka, E., Primc, N., Seoane, F., et al. (2026) · Transplant International · doi:10.3389/ti.2026.16316 · Cited by 4 · see citing works
“Across study designs, transplantation AI studies should report not only discrimination, but also calibration, external validation, subgroup performance, and the handling of missing data [32, 33].”
Сулейменова, М., Аbzaliyev, K., Abzaliyeva, S., & Nassyrova, N. (2026) · Applied Sciences · doi:10.3390/app16083903 · Cited by 2 · see citing works
Naeem, M. (2026) · Scientific Reports · doi:10.1038/s41598-026-54206-8 · Cited by 3 · see citing works
“We evaluate models across three dimensions: diagnostic performance, fairness, and statistical significance 41 .”
Thomsen, H. B., Lebiecka-Johansen, B., Nørgaard, O., Andersen, T. H., Andersen, S. T., Fagherazzi, G., Hulmán, Á., & Isaksen, A. A. (2026) · JMIR Diabetes · doi:10.2196/89374 · Cited by 1 · see citing works
“None of the studies reported any external validation or performance metrics beyond discrimination (AUC, sensitivity, and specificity), indicating modest performance [61].”
Cobo, V. T., Robles-Garcia, J. E., Guillén‐Grima, F., Lopez, A. C., Tapia-Tapia, M., Huerta, L. L., Ancizu-Marckert, F. J., Guillén-Aguinaga, L., Sánchez-Zalabardo, D., & López, B. M. (2026) · Diagnostics · doi:10.3390/diagnostics16101454 · Cited by 1 · see citing works
Hassan, B. D., & Zarif, S. (2026) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000005185 · Cited by 1 · see citing works
“Strong internal validation may, therefore, not be replicated in external populations with different case mixes, referral patterns, or perioperative protocols [ 5 ] .”
InfluentialLim, Y. X., Ming, L. C., Ng, N. C., Leow, S., & Ingle, R. G. (2026) · Discover Computing · doi:10.1007/s10791-026-10205-x · Cited by 2 · see citing works
“The coefficients from a logistic regression model, for example, provide a clear, quantifiable measure of a feature’s association with an outcome, which is fundamental to clinical guideline development and evidence-based practice [136].”
Bhuiyan, I., & Bhuiyan, T. (2026) · Big Data and Cognitive Computing · doi:10.3390/bdcc10070211 · Cited by 1 · see citing works
Naeem, M. (2026) · Applied Soft Computing · doi:10.1016/j.asoc.2026.115935 · Cited by 1 · see citing works
Bergonzo, S., Mouchabac, S., Auxéméry, Y., Kulakovskyi, A., Altunlu, E., Leboyer, M., Bonnot, O., Bourla, A., Koutsouleris, N., & Frileux, S. (2026) · L Encéphale · doi:10.1016/j.encep.2026.08.007 · Cited by 1 · see citing works
Li, L. Y., Lebiecka-Johansen, B., Byberg, S., Thambawita, V. L., & Hulmán, Á. (2026) · medRxiv · doi:10.64898/2026.04.17.26351092 · Cited by 1 · see citing works
Doeleman, T., Brussee, S., Valkema, P. A., Kempf, W., Vermeer, M. H., Kers, J., Wynaendts, L. C. D., Kerckhoffs, K. G. P., de Jonge, M. M., Nguyen, A. H., et al. (2026) · medRxiv · doi:10.64898/2026.07.27.26359009
Modellvalidierung und Gütekriterien
Prince, T., & Schmid, M. (2025) · Springer eBooks · doi:10.1007/978-3-662-63496-7_8-1
Wang, Y., Ishida, T., Wang, Z., et al. (2026) · Ophthalmology Retina · doi:10.1016/j.oret.2026.02.003
Deep Learning-Based Screening for POLE mutations on Histopathology Slides in Endometrial CancerPreprint
van den Berg, N., Schoenpflug, L. A., Horeweg, N., Volinsky-Fremond, S., Wolf, J. B., Andani, S., Lafarge, M. W., Ørtoft, G., Jobsen, J. J., Razack, R. R., et al. (2026) · medRxiv · doi:10.64898/2026.02.06.26345335 · Cited by 1 · see citing works
Self-citationZhao, W., Li, X., Zhang, X., Guo, Y., Zhang, B., Cao, Y., Diao, Y., Wu, Z., Lu, C., Chen, Z., et al. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03116-0 · Cited by 2 · see citing works
Jin, H., & Lee, H. (2026) · Applied Sciences · doi:10.3390/app16062735
Brunton, J., & Lawn, S. (2026) · Safety Science · doi:10.1016/j.ssci.2026.107169 · Cited by 2 · see citing works
Explainable Machine Learning for Multi-Horizon Early Sepsis Prediction in Intensive Care Units
Ogunwale, Y., Fakoya, J., Oyedemi, O. A., Abiona, A., Ajinaja, M., & Ibiyomi, M. A. (2026) · Cureus Journal of Computer Science · doi:10.7759/s44389-026-00045-7
Ganss, C., & Vach, K. (2026) · Caries Research · doi:10.1159/000551765 · Cited by 1 · see citing works
Evaluating biomarkers and prediction models with E2P SimulatorPreprint
Karvelis, P., Felsky, D., Abi-Dargham, A., Horga, G., & Diaconescu, A. O. (2026) · eLife · doi:10.7554/elife.110646.1
Evaluating biomarkers and prediction models with E2P SimulatorPreprint
Karvelis, P., Felsky, D., Abi-Dargham, A., Horga, G., & Diaconescu, A. O. (2026) · eLife · doi:10.7554/elife.110646
Ghazalbash, S., Zargoush, M., Guilcher, S. J. T., & Kuluski, K. (2026) · JMIR Medical Informatics · doi:10.2196/83244 · Cited by 1 · see citing works
Pilgram, L., Yang, K., Beltran-Bless, A.-A., et al. (2026) · Journal of Medical Internet Research · doi:10.2196/88665
“To facilitate interpretation of differences in calibration and discrimination, we conducted decision-curve analysis (DCA) for 5-year survival [45,46].”
Deep learning in population-based screening for glaucoma
Pitkänen, J., Hemelings, R., Ahokas, O., et al. (2026) · British Journal of Ophthalmology · doi:10.1136/bjo-2025-328523
Swee, S., Adam, I., Zheng, E. Y., Ji, E., Wang, D., Speier, W. F., Hsu, J., Chang, K.-W., Shivkumar, K., & Ping, P. (2026) · SSRN Electronic Journal · doi:10.64898/2026.04.21.26351421
Artificial intelligence models for lung cancer risk prediction using electronic health records
Islam, M. M., & Okere, A. N. (2026) · Health Sciences Review · doi:10.1016/j.hsr.2026.100269
Ramani, R. S., Jones, B., Chaurasia, A., Khazaei, Y., Schwärzler, J., Uribe, S. E., Schwendicke, F., & Tichý, A. (2026) · International Dental Journal · doi:10.1016/j.identj.2026.109566 · Cited by 2 · see citing works
Artificial Intelligence Applications in Pulmonary Hypertension: Current Status and Future Directions
Kohli, A., del Valle, K. T., & DuBrock, H. M. (2026) · Current Pulmonology Reports · doi:10.1007/s13665-026-00408-4
Chen, C., Asai, Y., Mochizuki, Y., Hagiwara, K., Okubo, R., Nakagawa, S., & Tabuchi, T. (2026) · Psychological Medicine · doi:10.1017/s0033291726104590
“We selected ROC AUC as the primary tuning metric because it is a widely used and recommended measure of discrimination in medical prediction research and captures performance across the full sensitivity – specificity tradeoff (Hajian-Tilaki, 2013; Van Calster et al., 2025).”
Artificial Intelligence as a Return on Investment Multiplier in Health Care
Ketcham, J. D. (2026) · NEJM AI · doi:10.1056/aipc2600139
Viktorov, E. I. (2026) · Regional and Branch Economy · doi:10.47576/2949-1916.2026.4.4.002
Wang, J., & Xu, Y. (2026) · Journal of Craniofacial Surgery · doi:10.1097/scs.0000000000012949
Demystifying Artificial Intelligence
Collins, J. E., Harari, R. E., & Duryea, J. (2026) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2026.04.001
Gao, C., Zhang, H., Zhang, R., et al. (2026) · BMC Medical Informatics and Decision Making · doi:10.1186/s12911-026-03609-8
“Calibration curves were combined with Brier scores (lower values indicate more accurate predictions) to assess the accuracy of probabilistic predictions [39].”
Varghese, J. S., Guo, J., Hua, D., Hung, T., Li, Z. T., Tang, S., Patel, S. A., & Ho, J. C. (2026) · medRxiv · doi:10.64898/2026.06.01.26354645
Créon, A., Magnani, M., Maas, C. C. H. M., van Diepen, M., Caldinelli, A., Russel, W. A., Dekker, F. W., Carrero, J. J., & Fu, E. L. (2026) · Clinical Kidney Journal · doi:10.1093/ckj/sfag187 · Cited by 1 · see citing works
“…and CKD-EPI) and filtration marker ( eGFR cr , eGFR cys , and eGFR cr-cys ) across four domains: discrimination, calibration, overall accuracy, and clinical utility, reporting all metrics recommended by the STRengthen-ing Analytical Thinking for Observational Studies ( STRATOS) initiative [ 20 ].”
Seghier, M. L. (2026) · International Journal of Imaging Systems and Technology · doi:10.1002/ima.70393
Machine learning in the diagnosis of Hirschsprung disease: a systematic review and meta-analysis
Liu, H. Y., Zhou, Y., Wang, X., Wang, C. Y., Guo, S., Sun, M., Li, S., & Wang, Y. (2026) · Pediatric Surgery International · doi:10.1007/s00383-026-06487-3
Kruthika, C. G., Krupa, K. S., & Sushma, E. (2026) · Journal of Pediatric Urology · doi:10.1016/j.jpurol.2026.106081
Grubinskienė, A., & Katkevičius, A. (2026) · IEEE Workshop on Advances in Information, Electronic and Electrical Engineering (AIEEE) · doi:10.1109/aieee71113.2026.11576907
“Following clinical-prediction-model guidance, this scale should be judged against calibration precision, predictor complexity, and the need to reserve data for temporal and external validation [21]-[26].”
InfluentialAI In Leukemia Diagnostics: Complementing the Pathologist's Role
Das, S. K., & Das, K. K. (2026) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.70193
“For clinical decision support, the question is not merely whether an AI model ranks cases correctly, but whether its probability estimates are trust-worthy enough to guide action [58].”
Predicting health and disease: a conceptual framework for AI in preventive and precision medicine
Barmada, A. (2026) · BMJ Health & Care Informatics · doi:10.1136/bmjhci-2025-101798
“20 However, the predictive performance itself may not necessarily translate into clinical utility or improved outcomes.”
Wei, Q., Cui, M., Qi, Y., Zhang, Q., Liu, Z., Yu, C., Hobbs, F. D. R., Christiani, D. C., Li, Y., Zhang, R., et al. (2026) · The Innovation Medicine · doi:10.59717/j.xinn-med.2026.100229
Jiang, Z. H. E. N. G. M., Liu, Y., Song, M., Chen, N., Yu, C., Lv, J., Wan, E. Y. F., Qi, L., Li, L., Sun, D., et al. (2026) · Advanced Science · doi:10.1002/advs.76345
“Calibration accuracy was further assessed using the calibration slope [ 55–57 ]; (4) Clinical utility was evaluated using decision curve analysis [ 58 ], with net benefit calculated across threshold probabilities from 0% to 2% and compared against the “intervention for all” and “intervention for…”
Polasi, S., Ramachandran, K., & Gokhale, A. V. (2026) · Journal of Gastroenterology · doi:10.1007/s00535-026-02470-w
Prediction model for early neurological deterioration in large artery atherosclerotic stroke
Feng, L., Zhang, C., Zhou, J., et al. (2026) · Frontiers in Neurology · doi:10.3389/fneur.2026.1868839
“…= 325) and 0.048 ( n = 108), respectively; Decision curve analysis (Figures 6A,B) indicated that the established prediction model appeared to confer favorable net clinical benefit across a broad range of threshold probabilities, providing preliminary support for its potential clinical utility (12).”
InfluentialMa, X. Y., Wang, Q., He, T., et al. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1891195
“…cohort, with calibration curves closely following the ideal 45° reference line. in the external validation cohort, intercept recalibration was performed, a common approach when predicted versus observed risks show systematic deviation across cohorts due to differences in baseline risk (32).”
Uribe, S. E., Carrasco‐Labra, A., Schwendicke, F., & Maldupa, I. (2026) · Caries Research · doi:10.1159/000553309
Xu, L. H., Liu, H., 张小娜, et al. (2026) · Transplant Infectious Disease · doi:10.1111/tid.70269
Computer Vision Approach to Triaging Patient-Submitted Photos of Intestinal Ostomies
Varghese, C., Choudhary, A., Larson, E. W., Lee, F., Baier, M., Glabe, C. L., Just, J. N., Friedrich, S., Merchea, A., Brady, J. T., et al. (2026) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0000000000004366
Deep Learning Applications for Automated Dental Arch Form Diagnosis
Shirdel, E., Azizipour, S., Magdalyanova, M., & Ашурко, И. П. (2026) · International Conference on Image Processing and Artificial Intelligence (ICIPAI) · doi:10.1109/icipai70034.2026.11605741
“This is particularly important for AI applications in dentistry and other medical settings, because from a clinical perspective, high accuracy is meaningful only when the model’s confidence is also reliable [34, 37].”
Tracy, A., Rashan, A., & Ranzani, O. (2026) · Current Opinion in Critical Care · doi:10.1097/mcc.0000000000001415
Hong, S., & Na, H. (2026) · Information · doi:10.3390/info17070712 · Cited by 1 · see citing works
“Consistent with recent recommendations for evaluating clinical AI, future studies should adopt multidimensional evaluation frameworks that integrate discrimination, calibration, agreement, interpretability, fairness, and clinical utility, rather than relying on a single performance metric [55].”
Artificial Intelligence in Public Health: Opportunities, Challenges, and the Path Forward
Kulkarni, H. R. (2026) · Journal of GMC Nagpur · doi:10.5005/jgmc-11030-0028
Güler, G. B., Güler, A., & Tanboga, I. H. (2026) · European Heart Journal - Digital Health · doi:10.1093/ehjdh/ztag120
“6,7 We also appreciate the correspondents’ point regarding validated operating thresholds.”
Abbas, A., Ravindran, D., Simone, M. C., et al. (2026) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.26.00014
Xu, K., Liu, J., Ji, Y., et al. (2026) · BMC Nephrology · doi:10.1186/s12882-026-05234-z
“…in the held-out internal test set were evaluated using the area under the receiver operating characteristic curve (AUC), accuracy, sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), F1 score, Cohen’s kappa, and Matthews correlation coefficient (MCC) [12].”
Thomsen, H. B., Andersen, S. T., Fagherazzi, G., et al. (2026) · doi:10.2196/preprints.105890
Prospective Deployment of Multimodal AI Grading for Medical Student OSCEsPreprint
Ngo, H.-T., Shakur, A. H., Holcomb, M. J., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-10475791/v1
Yuan, D.-F., Liu, Y.-Y., Liu, S.-S., Peng, N.-N., Zhu, X.-Y., Qian, Q.-J., Wang, B., & Yin, Y.-Q. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1846559
Boatemaa, A., Osei, B., & Forkuo, G. O. (2026) · Research Square · doi:10.21203/rs.3.rs-10560805/v1
Madbushi, S., pokharkar, S. T., & Golhar, Y. (2026) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/ggi.70731
Scott, I. A., van der Vegt, A. H., Campbell, V. K., Lane, P. J., Rice, M., & Venkatesh, B. (2026) · Journal of Evaluation in Clinical Practice · doi:10.1111/jep.70557
Scaling Expertise in Endometriosis Diagnosis: Can Artificial Intelligence Close the Gap?
Bajka, M., & Hoopmann, M. (2026) · Ultraschall in der Medizin - European Journal of Ultrasound · doi:10.1055/a-2876-6072
“Unfortunately, the current evidence for AI in clinical applications is still limited and of variable quality [33, 34], and in endo-metriosis, it is almost nonexistent.”
Haekal, M., Khotimah, S. N., Suwandi, G. R. F., & Haryanto, F. (2026) · Physiological Measurement · doi:10.1088/1361-6579/ae99aa
“This framing is aligned with contemporary guidance that AF burden should be interpreted together with monitoring duration and denominator, and that predictive models should be evaluated beyond discrimination alone (Doehner et al 2025, Van Calster et al 2025).”
From Medical Records to AI-Ready Datasets: A Practical Guide for Clinical Researchers
Anghel, C., Anghel, A. A., Crăciun, M., Moldovanu, S., Cocu, A., Vulpe, D. E., Maier, C., Potop, V., Dragosloveanu, C. D. M., Andrei, C. A., et al. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15166297
Multiscale Multiparametric MRI Deep Learning for Short‐Term Survival Assessment in Glioblastoma
Zhang, H., Zhou, B., Zhao, X., Jing, S., Zhang, H., Huang, B., Yang, Z., Wang, J., & Liu, Y. (2026) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.70497
Russu, E.-A., Ilinca, R., Popa, L. G., Dumitriu, A. S., Păunica, S., Giurcăneanu, C., & Albu, C.-C. (2026) · Pharmaceuticals · doi:10.3390/ph19081292
“Until these steps have been completed, the RTX-AI Response Framework should be interpreted exclusively as a conceptual architecture for future research and not as a clinical scoring system or decision-support instrument [65,76,77].”
Ghesquiere, M., Christinaki, E., Lemmens, S., Eijgen, J. V., Beeckmans, L., Ghinis, A., Jacobs, T., Keer, K. V., Wehbi, Z., Groef, L. D., et al. (2026) · Bioengineering · doi:10.3390/bioengineering13091041
Dlamini, N., Zulu, S., Nkosi, T., & Molefe, L. (2026) · International Journal Of Pharmaceutical Research And Allied Sciences · doi:10.51847/kowndomzzk
Zhang, M., He, S., Shi, H., et al. (2026) · Sustainability · doi:10.3390/su18168481
Eder, P. A., Moser, O., Rashid, A., Schlemm, E., Hessler, J., von Jouanne-Diedrich, H. K., Ziegler, V., & Soda, H. (2026) · Research Square · doi:10.21203/rs.3.rs-10095424/v1
Tingle, S. J., Kourounis, G., Kazerouni, S., Spiers, H. V. M., Larraz, M., Mehta, M., MacMillan, S., Hosgood, S. A., Nicholson, M. L., Sheerin, N., et al. (2026) · Scientific Reports · doi:10.1038/s41598-026-68541-3
Wang, X., Yao, G., Liu, H., & Ding, W. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1904589
“…observed-to-expected ratio, observed-versus-predicted risk by decile, and calibration plots), and clinical utility [decision-curve analysis (27)]; the selection and interpretation of these performance measures followed recent guidance for evaluating clinical prediction models that use ML (28).”
Hanif, F., Ahmed, A., & Raza, A. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1924216
Hung, M., Nelson, M., Chriss, H., Dhasi, S., Torp, K., & Mohajeri, A. (2026) · Discover Artificial Intelligence · doi:10.1007/s44163-026-02111-4 · Cited by 1 · see citing works
“Existing studies demonstrate substantial variability in model architecture, predictor selection, outcome definitions, and performance metrics, limiting comparability across studies and the synthesis of findings [11–13].”
Sun¹, Y., Zuo¹, Y., Pu², D., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-10543732/v1
张, 睿. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.1693044
Bozorgpour, R., Kim, P., & Rammer, J. R. (2026) · Journal of Imaging Informatics in Medicine · doi:10.1007/s10278-026-02245-y
Bhuiyan, I., Mirza, R., Hoque, A., et al. (2026) · FinTech · doi:10.3390/fintech5030077
Anderson, C. (2026) · medRxiv · doi:10.64898/2026.09.01.26361960
Prediction models for infection after kidney transplantation: a systematic review
Zhao, X., Zhang, Y., Tang, H., Long, J., Dong, H., Kuang, G., & Song, J. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1916764
“A complete calibration assessment should include at least a calibration plot, along with quantitative reporting of the calibration intercept and slope (44).”
Raynaud, M., Trayanova, N. A., Mannon, R. B., André, F., Doraiswamy, P. M., & Loupy, A. (2026) · Nature Reviews Bioengineering · doi:10.1038/s44222-026-00487-7 · Cited by 1 · see citing works
Responsible Implementation of EHR-Based Clinical Prediction Models—Beyond Performance
Zhao, S. J., & Deardorff, W. J. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.32906
Language models reflect clinical evidence but fail to adapt it to patientsPreprint
He, S., Joseph, J. W., Safari, P., Goff, A. C., Slusarz, P. J., Mohamed, A., Lord, S., Goldstein, J. N., & Raja, A. S. (2026) · medRxiv · doi:10.64898/2026.09.14.26363047
van den Berg, M. A., van Tulder, G., Ahedi, H., et al. (2026) · Osteoarthritis Imaging · doi:10.1016/j.ostima.2026.100472
Hubel, N. J., Prüfer, F., Bily, W., Schneider, D., Holzner, B., Fischer, M. J., & Grote, V. (2026) · Frontiers in Rehabilitation Sciences · doi:10.3389/fresc.2026.1930836
“Higher scores close to the maximum of 1 indicate better model performance for all the metrics above (58).”
Xavier, S. P., Victor, A., Gotine, A. R. M., et al. (2026) · PLoS ONE · doi:10.1371/journal.pone.0356621
İncir, S., Palaoğlu, K. E., & Oğuz, O. (2026) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2026-1371
“Validation then produces the same record in both cases: what was tested, against what standard, with what result, and who signed it [1, 37, 53, 54].”
Katifelis, H., Lappa, T., Poulopoulou, S., & Gazouli, M. (2026) · Medicina · doi:10.3390/medicina62091807
Washton, J., & Toma, M. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15187237
Hu, S., Yan, C., Tian, X., Xu, M., Cheng, B., Xu, T., & Cao, G. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1862258
Beyond Regulatory Approval: Lifecycle Assurance for Clinical Artificial Intelligence
Shujaat, S. (2026) · Journal of Medical Systems · doi:10.1007/s10916-026-02466-2 · Cited by 1 · see citing works
Predicting suicide attempts in people with autism and co-morbid mood or psychotic disordersPreprint
Baker, M. J., Lam, W. Y., Virtosu, M., & de Lacy, N. (2026) · medRxiv · doi:10.64898/2026.09.25.26364048
- Authors
- Van Calster, B., Collins, G. S., Vickers, A. J., Wynants, L., Kerr, K. F., Barreñada, L., Varoquaux, G., Singh, K., Moons, K. G., Hernandez-Boussard, T., Timmerman, D., McLernon, D. J., van Smeden, M., & Steyerberg, E. W.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Maastricht University (NL)
- University of Washington (US)
- KU Leuven (BE)
- Institut national de recherche en sciences et technologies du numérique (FR)
- University of California San Diego (US)
- Utrecht University (NL)
- University of Aberdeen (GB)
- Corresponding author
- Steyerberg, Ewout W
- ORCID
- Venue
- The Lancet Digital Health
- Publisher
- Elsevier BV
- Published
- 2025-12
- Volume
- 7
- Issue
- 12
- Pages
- 100916
- ISSN
- 2589-7500 (ISSN-L)
- OpenAlex
- W4417296978
- Semantic Scholar
- 3475c68ea3f9f7049202f1d964074c0ab5761021
- Cited by
- 112
- References
- 90
- Citations by year
- 2026: 111 · 2025: 1
- FWCI
- 6.62
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- The Lancet Digital Health (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion, cc-by)
- Leiden Repository (Leiden University) (submittedVersion, cc-by)
- Lirias (submittedVersion, cc-by)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion, cc-by)
- HAL (submittedVersion, cc-by)
- Aberdeen University Research Archive (Aberdeen University) (submittedVersion)
- Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
- Leiden Repository (Leiden University) (submittedVersion)
- Funders
- National Institutes of Health National Cancer Institute (P30CA008748)
- Engineering and Physical Sciences Research Council (EP/Y018516/1)
- National Center for Advancing Translational Sciences (C24/15/037, UL1TR003142, 12F3114N, G0B4716N, G049312N)
- Foundation for the National Institutes of Health
- Cancer Research UK (MR/V038168/1, C49297/A27294)
- Research Foundation Flanders (G097322N)
- National Institute of Diabetes and Digestive and Kidney Diseases (R42AI177108, ANR-22-PESN-0003, R01 DK093770, R01DK133226, R01EB030492)
- KU Leuven Research Council
- National Institute for Health and Care Research
- National Institutes of Health
- KU Leuven (C24M/20/064)
- National Library of Medicine
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek (9150172310023)
- Fight against Cancer
- Topics
- Health Sciences › Medicine › Health Informatics › Artificial Intelligence in Healthcare and Education
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Epidemiology
- Health Sciences › Health Professions › Health Information Management › Artificial Intelligence in Healthcare
- Keywords
- performance indicators, clinical decision support, binary outcome prediction, proper scoring rules, calibration, discrimination (statistics), clinical utility, net benefit, decision curve analysis, misclassification cost, ADNEX model, model validation
- MeSH terms
- Clinical Decision-Making, Artificial Intelligence, Humans
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Claims read by deepseek-v4.1-flash under definition version 3 (extract-v3) on 2026-10-09.
Classified by jev-1.13-20260917 (gold-guideline-v0.2) on 2026-10-09.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review